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Identification of the full spectrum of gene promoters methylated in cancer, or the cancer 
methylome, would greatly advance our understanding of gene regulatory networks involved 
in tumorigenesis. A robust approach was developed that couples genome-wide probabilistic 
search algorithms with an established pharmacologic unmasking strategy for unbiased and 
precise global localization of tumor-specific methylated genes. Through this approach, a set 
of 175 novel candidate genes was identified that cluster throughout the genome and may 
harbor cancer-specific promoter methylation. In this study, over sixty genes were tested in 
bladder and prostate cancer by candidate gene approach to evaluate new promising tumor 
suppressor genes in genitourinary cancer. An initial screen of the methylation status of the 
promoter region was conducted by bisulfite genomic sequencing in a panel of
 
over sixty 
genes in seven bladder cancer and four prostate cancer cell lines. Based on the bisulfite 
sequencing data, we selected nine genes (camk4, fkbp4, hoxB5, krt14, LPAR2, mal, rgs4, vgf 
and
 
ZMYM2) where aberrant methylation was detected in both bladder and prostate cancer 
cell lines. The expression of eight genes in carcinoma cell lines was analyzed by 
semiquantitative reverse transcription-PCR (RT-PCR) after 5-aza-2'-deoxycytidine treatment, 
alone or in combination with Trichostatin A. Methylation was detected by bisulfite 
sequencing in these genes at the following frequencies in bladder cancer cell lines: camk4 
(16.6%), fkbp4 (71.4%), hoxB5 (42.9%), krt14 (86%), LPAR2 (28.6%), mal (71.4%), rgs4 
(33.3%), vgf (57.1%), and ZMYM2 (57.1%). Methylation frequencies in prostate cancer cell 
lines were: camk4 (50%), fkbp4 (50%), hoxB5 (25%), krt14 (75%), LPAR2 (50%), mal 
(75%), rgs4 (50%), vgf (75%), and ZMYM2 (75%). RT-PCR analysis revealed re-expression 
of camk4, hoxB5, LPAR2, mal, rgs4, vgf, and ZMYM2 after 5-aza-2'-deoxycytidine treatment 
at least in one bladder cancer cell line and camk4, hoxB5, LPAR2, mal, rgs4, vgf, and 
ZMYM2 at least in one prostate cancer cell line. Previously unreported epigenetically altered 
genes in genitourinary cancer cell lines were identified. While further analysis is warranted in 
primary tissues, these results identify novel candidate tumor suppressor genes in bladder and 
prostate cancer. 
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Tumorigenesis represents a multistep process reflecting genetic alterations and genome 
instability acquired by gene mutations and disruption of growth signaling pathways (Hanahan 
and Weinberg, 2000). Under the common disease genetic and epigenetic hypothesis, the direct 
and indirect interaction of genetic and epigenetic variations determines age-related susceptibility 
to disease and cancer (Feinberg, 2008). The original definition of epigenetics by Waddington 
(Van Speybroeck, 2002)  phenotype arising under a program defined by the genome and 
environmental stimuli  embodies the concept of developmental biology. The modern definition 
of epigenetics refers to mitotically heritable aberrations of gene expression or function without 
changes of the DNA sequence. Cancer genesis involves both global and gene-specific hypo-
methylation and hypermethylation, accompanied by chromatin modifications (Feinberg, 2007). 
Epigenetic changes act synergistically with genetic alterations, and global hypomethylation 
along with hypermethylation of specific regulatory gene regions modify the functional state and 
drive pathologic silencing of growth controlling genes. 
 
Extensive loss of DNA methylation in colorectal tumors compared with matched normal mucosa 
was one of the first epigenetic aberrations discovered in human cancer (Feinberg and Vogelstein, 
1983). In the colon cancer cell line SW48, large genomic segments with hypomethylation reside 
almost exclusively in gene-poor areas (Weber et al., 2005). Hypomethylation occurs specifically 
at repetitive DNA sequences, such as short and long interspersed nuclear elements, long terminal 
repeat elements, and segmental duplications as well as subtelomeric regions whereas single copy, 
nonsubtelomeric DNA sequences rarely become demethylated (Rauch et al., 2008). Hypo-
methylation induces abnormal gene activation, genetic instability and chromosomal 
rearrangements (Feinberg and Tycko, 2004). 
 
De novo methylation of constitutively unmethylated clustered CpG dinucleotides in cytosine and 
guanine-rich “islands” has been proposed as a consequence of gene inactivation and has been 
shown to be the only impediment to transcription, since experimental de-methylation is sufficient 
for re-activation (Bird, 1986). Methylcytosine is highly susceptible to mutation through 
deamination to thymine (Duncan and Miller, 1980). Methylcytosine residues are located in short 
stretches of CpG-rich regions being 0.5-2 kb long and present in the 5’ region of approximately 
60% of genes. Using base compositional criteria, a CpG island (CGI) is defined as a 200 bp 
stretch of DNA with a C + G content greater or equal to 50 % and a CpGobserved/CpGexpected ratio 
greater or equal to 0.6 (Gardiner-Garden and Frommer, 1987). Increasing the stringency of the 
original criteria allowed the exclusion of Alu repetitive elements and CGIs not located within 
promoters (Takai and Jones, 2002). The observation that subsets of CGIs are coordinately 
methylated (Weisenberger et al., 2006) supports the proposal of a “CpG island methylator 
phenotype” (Toyota et al., 1999). The methylation status determines tissue-specific gene 
expression patterns in tissue-specific differentially methylated regions associated with 
5’ promoter CGIs; however, almost half of those identified differentially methylated regions are 
 - 2 - 
not associated with promoter CGIs in the mouse (Song et al., 2005). Tissue and cancer-specific 
differential methylation regions occur in “CpG island shores”, i.e. sequences located up to 2 kb 
distant from a promoter. Cancer-related differential methylation changes correspond to tissue-
specific methylation events during normal differentiation (Irizarry et al., 2009). These 
observations are consistent with the epigenetic progenitor model of cancer, which proposes that 
epigenetic alterations affecting tissue-specific differentiation represent the major mechanism by 
which epigenetic alterations drive cancer initiation and progression (Feinberg et al., 2006). 
 
De novo methylation of CGIs associated with promoter regions frequently induces gene silencing 
and represents a key component in tumor initiation and progression (Jones and Laird, 1999; 
Jones and Baylin, 2002). Loss of function of tumor suppressor genes (TSG) has been established 
as a central mechanism in the initiation and progression of human cancer (Vogelstein and 
Kinzler, 2004). Aberrant methylation of promoter region CGIs and subsequent gene silencing 
represent a crucial inactivating mechanism of TSG. Promoter cytosine hypermethylation in CGIs 
of a TSG in human cancer has first been described for the Retinoblastoma (Rb) gene (Greger et 
al., 1989), followed by the Von Hippel-Lindau gene (Herman et al., 1994), and p16
INK4a
 (Merlo 
et al., 1995). In colorectal cancer, epigenetic remodeling has been shown to induce gene 
suppression across an entire chromosomal band (Frigola et al., 2006). Promoter hyper-
methylation and the associated loss of gene expression can represent the “second genetic hit” in 
Knudson’s two-hit model of cancer genesis (Grady et al., 2000). 
 
The covalent transfer of the methyl group is being accomplished by the DNA-methyltransferases 
(DNMT) 1, 2, 3a, 3b and 3L targeting the 5’ carbon of the nucleotide cytosine in CpG sequences, 
proposedly via the formation of a carbanion. DNMT functionally cooperate and possess de novo 
as well as maintenance activity in vivo (Rhee et al., 2000; 2002). The source of the methylgroup 
is the dietary essential amino acid methionine being converted to the biologically active methyl-
donor S-adenosyl-methionine through a pathway involving folic acid (Giovanucci, 2004). The 
expression of DNMT1 is increased in cancer (Jones and Baylin, 2002), and increased expression 
of DNMT1 as well as local features based on sequence context determine the intrinsic 
susceptibility of individual CGIs to aberrant methylation (Feltus et al., 2003). 
 
Heritable repressive states are the manifestation of a complex interplay between DNA 
methylation, covalent histone modification and nucleosomal remodeling. The translation into 
transcriptionally inactive chromatin encompasses covalent histone modifications such as 
deacetylation catalyzed by histone deacetylases (HDAC) and trimethylation of lysine 9 in histone 
H3 (H3K9me3) or lysine 27 in histone H3 (H3K27me3), catalyzed by histone methyltransferases 
(HMT) (Jenuwein and Allis, 2001). There are mechanistic links between DNA methylation and 
chromatin silencing. Cytosine methylation attracts the methylated DNA binding protein MeCP2 
and a histone deacetylase core complex to methylated CGIs during chromatin compaction (Nan 
et al., 1998; Jones et al., 1998). Covalent histone modification also interacts with nucleosomal 
remodeling. The DNA methylation binding protein MBD2 interacts with the nucleosomal 
remodeling complex NuRD in a fashion that promotes DNA methylation (Zhang et al., 1999). 
Brahma, a component of the SWI/SNF chromatin-remodeling complex, links with MeCP2 
resulting in transcriptional silencing (Harikrishnan et al., 2005). Histone H3 lysine 4 tri-
methylation (H3K4me3) is coupled with a PHD finger of NURF, a nucleosomal remodeling 
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factor, leading to chromatin remodeling in an ATP-dependent reaction cascade (Li et al., 2006; 
Wysocka et al., 2006). DNMT1 directly interacts with the H3K9 methyltransferases G9a and 
SUV39H1 (Esteve et al., 2006). 
 
Nucleosomal occupancy represents one determinant of transcriptional control and CGI silencing 
in cancer. The conversion of the “open” or permissive state of a CGI for the initiation of 
transcription into a “closed” or repressed configuration is accompanied by a stable positioning of 
nucleosomes at transcription start sites. Erasure of DNA methylation by treatment with the 
DNMT inhibitor 5-aza-2’-deoxycytidine (5-aza-dC) leads to nucleosome depletion and 
reactivation of the three transcription start sites of the MLH1 promoter CGI (Lin et al., 2007). 
 
Endogenously expressed non-coding microRNAs (miRNAs) have gained attention as epigenetic 
regulators of gene expression. The miRNA-29 family has been shown to revert aberrant 
methylation by directly targeting DNMT3a and 3b mRNA in human lung cancer cells (Fabbri et 
al., 2007). De novo DNA methylation in differentiating mouse embryonic stem (ES) cells is 
regulated by miRNAs from the miRNA-290 cluster. Primary targets are transcriptional 
repressors contributing to downregulation of DNMT3 (Sinkkonen et al., 2008). During human 
prostate cancer progression, the genomic loss of miRNA-101 parallels an increase in expression 
of enhancer of zeste homolog 2 (EZH2), a H3K27 histone methyltransferase (Varambally et al., 
2008). In human primary bladder and prostate tumors, the tumor suppressor miRNA-126 is 
downregulated. Epigenetic treatment activates miRNA-126 and intronic miRNAs together with 
the host gene EGFL7 (Saito et al., 2009). 
 
In regard to invasive urinary bladder cancer the estimate of the numbers of new cases among 
men and women in the United States in 2008 is 68,810 and the expected number of deaths from 
bladder cancer projected for 2008 for both sexes combined is 14,100. The incidence rate for the 
time period 2000 to 2004 is 38.4 in men and 9.8 in women. In 2008, urinary bladder cancer 
accounts for about 7% of incident cases in men (Jemal et al., 2008). Histologically, more than 
90% of cases are transitional cell carcinoma (TCC), about 5% are squamous cell carcinoma, and 
less than 2% represent adenocarcinoma. Superficial “non-muscle-invasive” bladder tumors 
encompass a heterogenous group including cancers that are papillary and confined to the mucosa 
(Ta), high grade, flat and confined to the epithelium (Tis), and invasive forms extending into the 
submucosa or lamina propria (T1) (Pasin et al., 2008). Global genomic hypomethylation on 
pericentromeric satellite regions correlate with loss of heterozygosity (LOH) of chromosome 9p 
and 9q and activating mutations of FGFR3 and represent early genetic changes. Non-invasive 
papillary TCC is characterized by constitutive activation of the Ras-MAPK signal transduction 
pathway. With the acquisition of invasiveness, mutations of p53, loss of Rb, and homozygous 
deletion of INK4A contribute to inactivation of tumor-suppressor pathways. Deletions of 
chromosome 8p, loss of sFRP1 expression as well as the expression of genes involved in matrix 
remodeling represent markers for progression in papillary TCC (Wolff et al., 2005). 
 
The estimate of the numbers of new cases of invasive prostate cancer among men in the United 
States in 2008 is 186,320 and the expected number of deaths from prostate cancer projected for 
2008 for men is 28,660. The incidence rate for the time period 2000 to 2004 is 160.8, and in 
2008 it accounts for about 25% of incident cases in men (Jemal et al., 2008). 
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The approach of pharmacologic unmasking by treating cancer cell lines respectively with 5-aza-
dC (Jones and Taylor, 1980) alone or in combination with the histone deacetylase inhibitor, 
trichostatin A (TSA) (Cameron et al., 1999) for detecting TSG re-expressed on subsequent 
microarrays in combination with different algorithms represents a rapid genomic screening 
method to identify potentially relevant TSG (Suzuki et al., 2002; Yamashita et al., 2002). Further 
modification and improvement of candidate gene selection in conjunction with a novel promoter 
structure algorithm led to the identification of 200 candidate genes clustered throughout the 
genome. Testing for promoter methylation by bisulfite sequencing, methylation-specific PCR 
(MSP), and quantitative MSP (qMSP) revealed cancer-specific methylation in 28 genes (Hoque 
et al., 2008). 
 
Based on this candidate gene driven and global discovery-based approach, a set of over 60 genes 
has been screened in human bladder and prostate cancer cell lines for this study. Based on 
bisulfite sequencing, a high frequency of methylation could be detected in the following genes: 
calcium/calmodulin-dependent protein kinase IV (camk4), T-cell FK 506 binding protein 4 
(fkbp4), homeobox B5 (hoxB5), keratin 14 (krt14), lysophosphatidic acid G-protein-coupled 
receptor 2 (LPAR2), T-lymphocyte maturation-associated protein (mal), regulator of G protein 
signaling 4 (rgs4), VGF nerve growth factor inducible (vgf) and zinc finger, MYM-type 2 




camk4 has been assigned within the q21 to q23 long arm region of chromosome 5 (Sikela et al., 
1989). The gene product is a multifunctional member of the serine/threonine protein kinase 
family and the Ca
2+
/calmodulin-dependent protein kinase subfamily. Genetic mapping in the 
mouse positions camk4 in the centromeric region of chromosome 18 near two mutations 
affecting neurological function and fertility, underscoring the possibility that a gene defect may 
cause the mutant phenotype (Sikela at al., 1990). 
 
FK506-binding protein 4 (fkbp4) 
 
FK506-binding protein 4 was identified as a 59-kD protein in 9S, untransformed steroid receptor 
complexes in rabbit uterine and liver cytosols (Tai et al., 1986). The human 56-kDa protein co-
adsorbs 70-kDa heat shock protein (HSP70) and 90-kDa heat shock protein (HSP90) and is 
predominantly located in the cytoplasm (Sanchez et al., 1990). By using an FK506 affinity 
matrix to detect mammalian immunosuppressant-binding proteins, human fkbp4 has been shown 
to be an immunophilin with peptidyl-prolyl cis-trans isomerase (PPIase) activity that is inhibited 
by FK506 and rapamycin. It is a 56- to 59-kDa protein directly associating with the HSP90 in 
untransformed mammalian steroid receptor heterocomplexes. Human FKBP4 contains an 
N-linked glycosylation site, 12 protein kinase phosphorylation-site elements, representing four 
classes of motifs, and a calmodulin-binding site. FKBP4 localizes to the nucleus and cytoplasm 
(Peattie et al., 1992). The PPIase domain is crucial for dynein association and subsequent 
translocation of steroid receptors to the nucleus (Galigniana et al., 2001). The peroxysomal 
enzyme phytanoyl-CoA α-hydroxylase is a direct and specific target of FKBP4 and might be 
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involved in signal transmission by FKBP4 (Chambraud et al., 1999). The cochaperone consists 
of three domains: two FKBP12-like domains termed FK1 and FK2 and a C-terminal tetratrico-
peptide repeat (TPR) domain targeting binding to HSP90. The FK linker contains a consensus 
casein kinase II (CKII) phosphorylation site at T143 which regulates FKBP4-mediated 
potentiation of steroid hormone receptor activity. Wild-type FKBP52 and a phosphomimetic 
point mutant bind HSP90 equally well (Cox et al., 2007). In contrast, the blockade of FKBP4 
binding to HSP90 by phosphorylation found by Miyata et al. (1997) might be indicative of 
phosphorylation events at additional sites resulting in a functional down-regulation of FKBP4. 
Up-regulation of CKII activity accompanied by redistribution of individual subunits has been 
shown to be induced by inositol phosphates (Solyakov et al., 2004), hypoxic conditions in vitro 
(Mottet et al., 2005) and heat stress (Gerber et al., 2000). 
 
FKBP4 mediates the neurotrophic action of FK506 via activation of steroid receptor complexes 
(Gold et al., 1999). Ca
2+
-dependent cell death induced by an FKBP38-calmodulin-Ca
2+
 complex 
has been proposed to be mediated by antagonizing the anti-apoptotic protein Bcl-2 upon 
conditional activation (Edlich et al., 2006). Two neuroprotective, non-immunosuppressive 
immunophilin ligands designed by modification of rapamycin at the mammalian target of 
rapamycin binding site bind selectively to FKBP52 and to the β1 subunit of L-type voltage-gated 
calcium channels (Ruan et al., 2008). FKBP4 associates with the mammalian transient receptor 
potential (TRP) channel TRPC1, -C4, and -C5 orthologs (Sinkins et al., 2004). In the distal part 
of the nephron, active transepithelial Ca
2+
 reabsorption is being mediated by the epithelial TRP 
channel TRPV5. In an attempt to identify auxiliary proteins regulating channel activity, FKBP4 
has been found to co-localize with TRPV5 and to inhibit Ca
2+
 influx by virtue of its PPIase 
domain. The specific inhibitory interaction results in a significant decrease of Ca
2+
 influx 
through TRPV5, an effect that is being reversed by siRNA gene silencing of FKBP4 or 
administration of the immunosuppressive drug FK-506 (Gkika et al., 2006). 
 
FKBP4 and androgen receptor (AR) are co-expressed in prostate epithelial cells of wild-type 
mice. Male mice lacking FKBP4 show defects in reproductive tissues such as dysgenesis of 
anterior prostate consistent with androgen insensitivity. By virtue of its PPIase activity and 
HSP90 binding domain FKBP4 can enhance AR-mediated transactivation by targeting AR-




Mesenchymally derived homeobox genes represent highly conserved developmental regulatory 
genes coding for transcription factors. Originally identified in Drosophila melanogaster as genes 
leading to homeotic transformation (Lewis, 1978), the ancient HOX cluster underwent 
duplications and gene losses resulting in the 39 current mammalian HOX genes organized into 
four distinct clusters (Garcia-Fernandez, 2005). Human homeobox region 2 has been mapped to 
17q21→q22 and is closely linked to the nerve growth factor receptor gene (Xu et al., 1988). 
Homeobox proteins are classified based on their conserved 61-amino acid helix-loop-helix 
DNA-binding motif, the homeodomain (Gehring et al., 1994). 
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HoxB5 is required for normal human lung airway branching morphogenesis and controls 
embryonic bronchiolar “patterning”. Similar to mouse lung development, HoxB5 protein shows 
distinct temporal, spatial, and cellular expression characteristics. Expression levels are high in 
the pseudoglandular period, decreased in the canalicular period and negligible during the 




Lysophosphatidic acid (LPA) is generated by phospholipase cleavage of membrane 
phospholipids. Its cellular activities are mediated by G protein-coupled receptors (GPCRs). 
LPAR2 encodes a subtype of functional GPCR for LPA and mediates LPA-induced 
transcriptional activation of a serum response element-driven reporter gene by coupling to a Gi 
protein to inhibit adenylyl cyclase and to Rho GTPase (An et al., 1998a). Mobilization of 
intracellular Ca
2+
 through inositol triphosphate generated by phospholipase C activation 
represents a major cellular response to LPA (An et al., 1998b). LPAR2 transduces Ca
2+
 
mobilization through pertussis toxin-sensitive Gi and Gq proteins. 
 
mal (T-lymphocyte maturation-associated protein) 
 
Human mal cDNA was isolated from a subtracted T-cell library and encodes a 16.7 kDa 
hydrophobic integral membrane protein expressed in the intermediate and late stages of T-cell 
differentiation (Alonso and Weissman, 1987). By using somatic hybrid cell lines, Alonso et al. 
(1988) assigned the mal gene to human chromosome 2cen-q13. The MAL proteolipid is 
localized to cholesterol-enriched structures such as post-Golgi vesicles, early endosomes and the 
plasma membrane. It is a component of the detergent-resistant membrane microdomains 
representing T-cell insoluble complexes and co-localizes with tyrosine kinases of the src family, 
such as p56lck or p59fyn (Stefanová et al., 1991), the glycosylphosphatidylinositol-anchored 
protein CD59 and the ganglioside GM1 (Millán et al., 1997). It carries out a central function in 
apical membrane transport which is subject to functional disturbances in neoplastic tissue 




rgs4 contains five exons, spans 5.5 kb and has been mapped to 1q23.3 (Sierra et al., 2002). 
rgs4 encodes structural and functional homologues of the yeast SST2 gene product, Sst2p which 
negatively regulates G protein signaling and induces desensitization in yeast (Chan and Otte, 
1982). Introduction of RGS4 into yeast reduces signal transduction through the pheromone-
response pathway. RGS proteins share the RGS domains, a conserved 130 amino acid motif 
related to a region in Sst2p (Koelle and Horvitz, 1996; Popov et al., 1997). This domain is 
closely related to a region in the protein flbA encoded by an SST2-related gene in Aspergillus 
nidulans (Adams et al., 1992). 
 
RGS proteins are regulatory and structural components of G-protein coupled receptor complexes. 
Because RGS can directly bind to Giα (De Vries et al., 1995), their mode of action might target 
the G protein directly. Rgs4 represents a cytoplasmic GTPase activating protein (GAP) for Gi- 
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and Gq-class Gα subunits of heterotrimeric G proteins (Berman et al., 1996). The protein product 
deactivates G protein subunits of the Giα, Goα and Gqα subtypes by driving the equilibrium of the 
reaction towards the inactive GDP-bound conformation. Functionally, this protein negatively 
regulates signaling pathways upstream or at the level of the heterotrimeric G protein (Druey et 
al., 1996). 
 
The first RGS family member, RGS1, was classified as a B-lymphocyte-specific gene activated 
in chronic lymphocytic leukemia (Hong et al., 1993; Newton et al., 1993). RGS2 was isolated by 
a clone from a blood monocyte cDNA library (Siderovski et al., 1994). RGS4 was identified in a 
screen of rat brain cDNA. The protein of the human orthologue has 97% amino acid identity 
with rat RGS4. It encodes a protein of 205 amino acids, with 37% identity to RGS1. In vitro 
studies with 293T cells permanently transfected with interleukin (IL)-8 show a significant 
reduction of extracellular-signal regulated kinase (ERK) 1 activity in response to IL-8. RGS1 
expression in B-cell lymphoma cells significantly decreases platelet-activating factor (PAF)-
induced mitogen-activated kinase (MAPK) activity. Furthermore, PAF could be shown to induce 
RGS1 expression, which in turn inhibited PAF-induced increases in MAPK activity, suggesting a 
negative feedback loop to limit signal transduction through the PAF receptor (Druey et al., 
1996). MAPK activation by mammalian G-protein-linked receptors is significantly impaired. 
 
An RGS family member in Caenorhabditis elegans, egl-10, negatively regulates signaling 
through the homologue of the mammalian Go protein upstream of the G protein (Koelle and 
Horvitz, 1996). 
 
Region-specific regulation of RGS4 expression in the brain by stress and glucocorticoids (Ni et 
al., 1999) may suggest a role for RGS4 in stress adaptation. Because GAP activity of RGS4 
regulates the duration of intracellular postsynaptic signaling for Gi, Go and Gq-coupled 
neurotransmitter receptors (De Vries et al., 2000), genetic association and linkage analysis using 
RGS4 polymorphisms aimed to identify susceptibility genes for schizophrenia. Rgs4 expression 
analysis of postmortem cerebral cortex is decreased in patients with schizophrenia. Significant 
associations involve SNPs 1, 4, 7, and 18 within a 10-kb span of rgs4 (Chowdari et al., 2002). 
The association of RGS4 polymorphisms with morphometric differences in the dorsolateral 
prefrontal cortex of first-episode schizophrenia patients might indicate a role of RGS4 poly-
morphisms in inducing structural alterations in the prefrontal cortex (Prasad et al., 2005). 
However, Sobell et al. (2005) failed to confirm an association of RGS4 SNP alleles or of 
particular 4, 3, or 2 SNP haplotype. 
 
vgf nerve growth factor inducible 
 
vgf was originally cloned by Levi et al. (1985) as a gene sequence induced in rat pheochromo-
cytoma cells by nerve growth factor (NGF) and has been proposed as one of the primary events 
in NGF-induced neuronal differentiation. Determination of the complete coding sequence and 
characterization of the promoter region of the cloned rat gene identified a consensus binding site 
for the cAMP response element-binding protein (CREB) at position  71, four GC box motifs as 
well as two elements resembling AP-2 binding site consensus sequences (Salton et al., 1991). 
The CREB site has been found to regulate gene expression via protein kinase A or calcium-
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calmodulin-dependent protein kinase pathways (Montminy et al., 1986; Montminy and 
Bilezikjan, 1987; Sheng et al., 1990). Because the cAMP-dependent protein kinase A pathway is 
not strongly implicated in vgf regulation (Salton et al., 1991), calcium-calmodulin-dependent 
protein kinase pathways seem to be of higher importance in the regulation of vgf by cell 
depolarization. 
 
The single transcript of 2.7 kb detected only in brain mRNA was mapped on chromosome 7q22 
and is a single copy gene in humans (Canu et al., 1997). vgf encodes for a 68 kDa protein 
belonging to the chromogranin family secreted by neuroendocrine cells (Feldman and Eiden, 
2003). Undergoing cell-type specific proVGF processing, proVGF-related peptides are present in 
human endocrine cells and are significantly increased in hyperplasia and endocrine tumors in 
vivo suggesting an active role of the endocrine cell in response to specific growth related stimuli 




The stem cell leukemia/lymphoma syndrome is characterized by an immature T-cell immuno-
phenotype and presents with T-cell lymphoblastic lymphoma, myeloproliferation, peripheral 
eosinophilia, and a rapid progression to acute myeloid leukemia. It is associated with three 
different translocations. Chromosomal band 8p11-12 can rearrange with a partner at 6q27, 
9q32-34, or 13q12 with fibroblast growth factor receptor 1 (FGFR1) being involved in all three 
rearrangements, supporting its oncogenic role (Popovici et al., 1998). The specific reciprocal 
chromosome translocation, t(8;13)(p11;q11-12) (Abruzzo et al., 1993; Inhorn et al., 1995) also 
involves an inversion of a region of 13q-12 that contains the znf198 gene (Reiter et al., 1998). 
B-cell and biphenotypic variants have also been reported (Childs et al., 1986; Sheibani et al., 
1987). 
 
The t(8;13) translocation breakpoint may harbor putative oncogenes and TSG crucial for normal 
hematopoiesis and leukemogenesis. FGFR1 is located at 8p12-p11.2. The 8p11 translocation 
breakpoints cluster within intron 8 of FGFR1 and are associated with aberrant transcripts 
revealing an in-frame fusion of four N-terminal atypical zinc finger domains and proline-rich 
domains of znf198 and the C-terminal tyrosine-kinase domain of FGFR1. The reciprocal fusion 
transcript directs the synthesis of a predominantly cytoplasmic oncogenic chimeric 87-kD 
polypeptide and has been proposed to promote hematopoietic stem cell proliferation and 
progression of the myeloproliferative disorder by constitutive activation of FGFR1 tyrosine 
kinase (Xiao et al., 1998; Smedley et al., 1998) or by an alteration of normal ZNF198 protein via 
heterodimer formation (Xiao et al., 1998). 
 
znf198 has been mapped to locus 13q11-q12 and shows significant homology to DXS6673E, 
a candidate gene in X-linked mental retardation located at Xq13.1 (Xiao et al., 1998). The novel, 
putative metal-binding motif is present as five tandem repeats in znf198 and DXS6673E and 
resembles zinc-binding sequences (Smedley et al., 1998). Alignment of the predicted amino acid 
sequences of ZNF198, KIAA0385, and KIAA0425 revealed a novel, conserved Zn-finger-related 
motif, termed MYM domain that was repeated five times in each protein. Conceptual translation 
of the znf198 cDNA predicted a 1377 amino acid protein of 155 kD (Reiter at al., 1998). 
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Because of their ability to dimerize in their native form (Luisi et al., 1991), znf198 Cys-Cys-Cys-
Cys zinc fingers can potentially dimerize in a ligand-independent fashion, thereby constituting 
tyrosine kinase activation of the ZNF198-FGFR1 oncoprotein (Xiao et al., 1998). The widely 
expressed hydrophilic ZNF198 protein exists in two isoforms containing either four or ten 
putative atypical zinc fingers, two proline repeats and a consensus carboxy-terminal acidic 
activation domain (Still and Cowell, 1998). A putative bipartite nuclear localization signal 
suggests its function as a regulator of transcription (Popovici et al., 1998). 
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Materials and Methods 
 
Cell Lines and Tissue Samples 
 
Bladder cancer cell lines 5637, HT-1376, J82, SCaBER, SW780, T24, UM-UC3 and prostate 
cancer cell lines DU-145, LNCaP, PC-3, 22Rv1 were obtained from and propagated according to 
the recommendations of ATCC (Manassas, VA, USA). Media and antibiotics were purchased 
from Mediatech (Manassas, VA, USA) and supplemented with fetal bovine serum (10%) 
(Hyclone, Logan, UT, USA), 100 g/ml streptomycin, and 100 I.U./ml penicillin. Cells were 
grown at 37 C in a humidified atmosphere composed of 95% air and 5% CO2 in a monolayer 
culture. HT-1376, SCaBER, UM-UC3, and DU-145 were maintained in MEM, SW780 was 
grown in Leibovitz’s L-15 medium, J82 was grown in DMEM. 5637, LNCaP and 22Rv1 were 
maintained in RPMI 1640, T24 was grown in McCoy’s 5A medium, and PC-3 was grown in 
Ham’s F-12K medium. Human primary bladder tumors and matched normal bladder tissues was 
kindly provided by Dr. D. Berman, Department of Pathology, The Johns Hopkins University. 
cDNA from sixteen human prostate cancer specimens and matched normal cDNA was kindly 
provided by Dr. A. M. DeMarzo, Department of Pathology, The Johns Hopkins University. 
The patients gave written informed consent for sample collection according to institutional 
guidelines. 
 
DNA and RNA Extraction 
 
Cell pellets were digested with 1 % SDS and 50 μg/ml proteinase K (Roche, Mannheim) at 48˚C 
overnight. Isolation of genomic DNA from cell lines was performed either with phenol 
(Sambrook et al., 1989) or with the FlexiGene DNA kit (Qiagen, Hilden, Germany). Bladder 
tissue samples were digested with 1 % SDS and 50 μg/ml proteinase K at 48˚C overnight 
followed by the addition of 20 % SDS and 100 μg/ml proteinase K twice over a period of 
36 hours. DNA from tissue was extracted with phenol by using MaXtract High Density tubes 
(Qiagen). For RNA extraction, adherent cells were detached by addition of RNAprotect Cell 
Reagent (Qiagen), followed by the procedure of the RNeasy Plus Mini kit (Qiagen). RNA 
extraction from bladder tissue was performed with the phenol-guanidine-based QIAzol Lysis 
Reagent (Qiagen). 
 
Bisulfite-Modification of DNA, PCR Amplification and Sequencing Analysis 
 
Sodium bisulfite-mediated conversion of unmethylated cytosines in DNA was performed with 
the EpiTect Bisulfite Kit (Qiagen). 2 g of cell line DNA and 0.5, 3 or 5 g of bladder tissue 
DNA were processed. 2 l bisulfite-converted genomic DNA was amplified by primers designed 
using the MethPrimer algorithm (Li and Dahiya, 2002). DNA was amplified for the 5’ region 
including a portion of the CpG island within 1 kb of the transcriptional start site. Primer 
sequences were designed to hybridize to promoter regions without CpG dinucleotides and are 
indicated in Supplemental Table S1. The final concentration of dNTPs and primers in the 
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reaction were 6.25 mM and 2.1 M, respectively. 2.5 units Platinum Taq DNA Polymerase 
(Invitrogen, Carlsbad, CA) were added and the reaction was carried out in a GeneAmp  PCR 
System 9700 (Applied Biosystems, Foster City, CA, USA) under the following conditions: 
95.0 C for 3 min, followed by 95.0 C for 30 sec, 56 C for 30 sec, 72.0 C for 1 min for 2 cycles, 
95.0 C for 30 sec, 54 C for 30 sec, 72.0 C for 1 min for 2 cycles, 95.0 C for 30 sec, 52 C for 30 
sec, 72.0 C for 1 min for 2 cycles, 95.0 C for 30 sec, 50 C for 30 sec, 72.0 C for 1 min for 
2 cycles, 95.0 C for 30 sec, 48 C for 30 sec, 72.0 C for 1 min for 40 cycles, and extension at 
72.0 C for 7 min. β-actin served as an internal control. PCR products were separated by 
electrophoresis on 1.5 % agarose gels stained with ethidium bromide and imaged in the Gel Doc 
XR with Quantity One Version 4.6.1. software (Bio-Rad, Hercules, CA, USA). 
 
Upon visualization by electrophoresis, PCR products were extracted according to the QIAquick 
gel extraction protocol (Qiagen) and sequenced by the 3730xl DNA Analyzer (Applied 
Biosystems) using the BigDye Terminator v3.1 cycle sequencing kit and forward or reverse 
primers. The data were analyzed using the Sequence Scanner v1.0 software (Applied 
Biosystems). A methylation frequency of  50% of total CpG sites within the amplified region 
was considered “methylation-positive” (M). 
 
5-Aza-2’-deoxycytidine Treatment of Cell Lines 
 
24 h before treatment, cells were plated at low density (1-3 10
6
 cell concentration, in 
dependence on growth characteristics of the respective cell line) in 250 ml Tissue Culture Flasks 
(BD Biosciences, Bedford, MA, USA). 100 mM stock solutions of 5-Aza-dC (Sigma, St. Louis, 
MO, USA) and 3 mM stock solutions of TSA (Sigma) were prepared in DMSO (Sigma). 
Immediately before addition to the cell culture medium, appropriate aliquots of the stock 
solutions were dissolved in PBS (pH 7.5). Following renewal of cell culture medium cells were 
treated with 5 M 5-Aza-dC every 24 h over a course of three and five days. Cells were also 
treated with 5-Aza-dC every 24 hr over a course of three and five days in combination with 
300 nM TSA administered 24 hr before harvesting cells. Controls were mock treated with 
corresponding volumes of DMSO dissolved in PBS. DNA and RNA were extracted on day 4 




For semi-quantitative RT-PCR, total RNA from cell lines and from bladder tissue was reverse-
transcribed with SuperScript III First-strand Synthesis SuperMix (Invitrogen) using random 
hexamers. 1 l of cDNA was subjected to PCR amplification. The primers were designed based 
on two different exons by means of Primer3 software (Rozen and Skaletsky, 2000). Primer 
sequences are indicated in Supplemental Table S2 and were confirmed by gel-extraction 
according to the QIAquick gel extraction protocol (Qiagen) and sequencing using the BigDye 
Terminator v3.1 cycle sequencing kit and the 3730xl DNA Analyzer (Applied Biosystems). The 
final concentration of dNTPs and primers in the reaction were 0.2 mM and 1 M, respectively. 
1.0 unit Platinum Taq DNA Polymerase (Invitrogen) was added, and the reactions were 
incubated in a PTC-200 DNA Engine Peltier Thermal Cycler (MJ Research, Inc./Bio-Rad). 
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The conditions for camk4, LPAR2, and ZMYM2 were 94.0 C for 2 min, followed by 94.0 C for 
45 sec, 58 C for 45 sec, 72.0 C for 1 min for 40 cycles, and extension at 72.0 C for 7 min. 
Conditions for hoxB5, fkbp4 and rgs4 were 94.0 C for 2 min, followed by 94.0 C for 45 sec, 
59 C for 45 sec, 72.0 C for 1 min for 40 cycles, and extension at 72.0 C for 7 min. Conditions 
for mal were 94.0 C for 2 min, followed by 95.0 C for 45 sec, 60 C for 45 sec, 72.0 C for 1 min 
for 35 cycles, and extension at 72.0 C for 7 min. Conditions for vgf were 94.0 C for 2 min, 
followed by 95.0 C for 45 sec, 62 C for 45 sec, 72.0 C for 1 min for 35 cycles, and extension at 
72.0 C for 7 min. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an internal 
control. The reactions were carried out as triplicates. PCR products of cell lines were separated 
by electrophoresis on 1.5 % agarose gels stained with ethidium bromide and imaged in the Gel 
Doc XR (Bio-Rad). PCR products of bladder tissue samples were separated on PAGEr  Gold 
10% TBE precast gels (Lonza, Rockland, ME, USA) with the addition of GelStar  Nucleic Acid 
Gel Stain (Lonza) to the loading buffer (Bio-Rad). 
 
Methylation-specific PCR and Quantitative Real-Time MSP 
 
Bisulfite-modified genomic DNA served as a template for MSP and qMSP. Discrimination of 
sequence differences is made by primers annealing specifically with either the converted 
methylated (M) or converted unmethylated sequence (U) (Herman et al., 1996). Primers were 
designed using the MethPrimer algorithm (Li and Dahiya, 2002) and MSPprimer algorithm 
(Brandes et al., 2007). qMSP represents a highly sensitive, sequence-specific and quantitative 
assay utilizing fluorescence-based real-time PCR (TaqMan
®
) technology and detects methylated 
alleles in the presence of a 10,000-fold excess of unmethylated alleles (Eads et al., 2000). 
Primers were designed to hybridize to a region determined to be methylated in cell lines by 
bisulfite sequencing, and a fluorescent probe was designed to the amplified DNA region. 
Oligonucleotide primer pairs were purchased from Invitrogen, and the probes were purchased 
from Eurogentec (San Diego, CA). β-actin served as a reference gene. Sequences are provided in 
Supplemental Table S3. Serial dilutions (90 − 0.009 ng) of in vitro CpG methyltransferase SssI-
methylated (New England BioLabs, Ipswich, MA) human leukocyte genomic DNA from a 
healthy donor were used to construct a calibration curve for each plate. Amplification reactions 
were carried out in duplicate in a final volume of 20 μl containing 3 μl bisulfite-modified DNA, 
600nmol/l forward and reverse primers, 200 nmol/l probe, 0.6 unit Platinum Taq DNA 
Polymerase (Invitrogen), dATP, dCTP, dGTP, and dTTP in a concentration of 200 μmol/l, 
respectively, and 6.7 mmol/l MgCl2. Amplification reactions were carried out in 384-well plates 
in a 7900HT Fast Real-Time PCR System (Applied Biosystems) and were analyzed by the 
Sequence Detector System software (SDS 2.3; Applied Biosystems). Primer and probe 
sequences and annealing temperatures are provided in Supplemental Table S3. 
 
The samples were within the assay’s range of sensitivity and reproducibility based on the 
amplification of the internal reference standard [threshold cycle (CT) value for β-actin of 40]. 
The relative level of methylated DNA for each gene in each sample was determined as a ratio of 
MSP for the amplified gene to β-actin, multiplied by 1000 for easier tabulation [(average value 
of duplicates of gene of interest ÷ average value of duplicates of β-actin)  1000] [TaqMan 
methylation value (TaqMeth V)]. The threshold of the assay was determined by maximizing 
 - 13 - 
sensitivity and specificity. The samples were categorized as methylated or unmethylated based 
on detection of methylation above a threshold set for each gene. This threshold was determined 




To test differences in methylation frequency of the gene evaluation set, Fisher’s exact method 
has been applied. In the test set, normal vs. tumor methylation values were compared using 
boxplots (Tukey, 1977) of the log-transformed values. The length of the box represents the 
interquartile range of data and depicts the spread of the middle 50% of the observations. The 
median is shown as a horizontal line inside the box. Lines extending from the upper and lower 
quartiles represent adjacent values defined as the upper quartile plus 1.5  interquartile range and 
the lower quartile minus 1.5  interquartile range. Values outside of this range are considered 
outliers and are shown as open circles. 
 
The presence or absence of methylation in association with cancer was evaluated using cross-
tabulations and χ
2
 or Fisher’s exact test. Continuous methylation levels were evaluated using 
logistic regression (Cox, 1970). Internal validation of the logistic regression models was done 
using an approximation to the leave-one-out jackknife procedure provided by the SAS 
classification table option (SAS/STAT 9.2 User’s Guide. Cary (NC): SAS Institute Inc.). 
The methylation index was calculated as the total number of genes showing any methylation 
divided by the total number of genes examined. Correlations of the methylation levels of genes 
were calculated with Spearman correlation coefficients. 
 - 14 - 
Results 
 
An initial screen of the methylation status of the promoter region was conducted by bisulfite 
genomic sequencing in a panel of
 
over sixty genes in seven bladder cancer and four prostate 
cancer cell lines (Table 1). The candidate genes showing high frequency of promoter DNA 
methylation in bladder and prostate cancer cell lines based on bisulfite sequencing are depicted 
in Table 2. Based on the bisulfite sequencing data, we selected nine genes (camk4, fkbp4, hoxB5, 
krt14, LPAR2, mal, rgs4, vgf and
 
ZMYM2) where aberrant methylation was detected in both 
bladder and prostate cancer cell lines. The known or proposed function of these genes is 
summarized in Table 3. The methylation status of the promoter regions in regard to the cell lines 
is shown in Table 4 and 5. A methylation frequency of ≥ 50% of total CpG sites within the 
amplified region was considered “methylation-positive” (M). Methylation was detected by 
bisulfite sequencing in these genes at the following frequencies in bladder cancer cell lines: 
camk4 (16.6%), fkbp4 (71.4%), hoxB5 (42.9%), krt14 (86%), LPAR2 (28.6%), mal (71.4%), rgs4 
(33.3%), vgf (57.1%), and ZMYM2 (57.1%). Methylation frequencies in prostate cancer cell lines
 
were: camk4 (50%), fkbp4 (50%), hoxB5 (25%), krt14 (75%), LPAR2 (50%), mal (75%), rgs4 
(50%), vgf (75%), and ZMYM2 (75%) (Table 2). 
 
 
Table 1. Cell lines used in this study 
 
Cell Line Source 
5637 Human urinary bladder; carcinoma, grade II 
HT-1376 Human urinary bladder; carcinoma, grade III 
J82 Human urinary bladder; transitional cell carcinoma 
SCaBER Human urinary bladder; squamous cell carcinoma 
SW780 Human urinary bladder; transitional cell carcinoma 
T24 Human urinary bladder; transitional cell carcinoma 
UM-UC3 Human urinary bladder; transitional cell carcinoma 
  
DU145 
Human prostate carcinoma, 
derived from metastatic site: brain 
LNCaP clone FGC 
Human prostate carcinoma, 
derived from metastatic site: left supraventricular lymph node 
PC-3 
Human prostate adenocarcinoma, stage IV, 
derived from metastatic site: bone 
22Rv1 Human prostate carcinoma 
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protein kinase IV 




15q15 3/7  43 % 1/4  25 % 
NM_002014 fkbp4 FK506 binding protein 4 12p13.33 5/7  71.4 % 2/4  50 % 
NM_000403 gale UDP galactose-4-epimerase 1p36-p35 7/7  100 % 4/4  100 % 
NM_002147 hoxB5 homeobox B5 17q21.3 3/7  42.9 % 1/4  25 % 
NM_002151 hpn 
hepsin (transmembrane 
protease, serine 1) 
19q11-q13.2 5/7  71 % 3/4  75 % 
NM_005552 kns2 KLC1 (kinesin light chain 1) 14q32.3 0/6  0 % 1/4  25 % 








2cen-q13 5/7  71.4 % 3/4  75 % 




Xp11.4 3/7  43 % 1/3  33 % 
NM_000267 nf1 neurofibromin 1 17q11.2 7/7  100 % 2/4  50 % 
NM_014476 pdlim3 PDZ and LIM domain 3 4q35 2/6  33 % 1/4  25 % 
NM_000292 phka2 phosphorylase kinase, α2 Xp22.2-p22.1 1/6  17 % 0/4  0 % 
NM_002855 pvrl1 poliovirus receptor-related 1 11q23.3 1/6  17 % 0/4  0 % 
NM_005613 rgs4 
regulator of G protein 
signaling 4, isoform 2 




6q23 1/6  17 % 0/4  0 % 
NM_003378 vgf 
VGF nerve growth factor 
inducible precursor 
7q22 4/7  57.1 % 3/4  75 % 
NM_003453 ZMYM2 zinc finger, MYM-type 2 13q11-q12 4/7  57.1 % 3/4  75 % 
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Table 3. Known or proposed function of selected candidate genes with high frequency of 





Known or Proposed Function 
 
NM_001744 camk4 
multifunctional serine/threonine protein kinase; transcription 




 mobilization through association with Gi and Gq proteins; 
LIM domain binding; lipid binding; protein binding; receptor activity 
NM_002014 fkbp4 
GTP binding; glucocorticoid receptor binding; heat shock protein 
binding; phosphoprotein- and protein binding; activation of Wnt 
pathway 
NM_002147 hoxB5 sequence-specific DNA binding; transcription factor activity 
NM_000526 krt14 
structural constituent of cytoskeleton and epidermis; protein binding; 
role in binding to TNF-α receptor-associated death domain (TRADD) 
and in susceptibility of keratinocytes to caspase-8-mediated apoptosis 
NM_002371 mal apoptotic protease activator activity; channel activity; lipid binding 
NM_005613 rgs4 
GTPase activator activity; calmodulin binding; 
negative regulation of signal transduction; 
inactivation of MAPK activity 
NM_003378 vgf growth factor activity; neuropeptide hormone activity 
NM_003453 ZMYM2 
activation of AKT and MAPK pro-survival signaling pathways; 
regulation of transcription; metal ion binding; protein binding;  
zinc ion binding 
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Table 4. Promoter DNA methylation status of each candidate gene depicted for bladder 
cancer cell lines. Methylation was evaluated by direct sequencing. M, harbor methylated 
alleles; U, harbor unmethylated alleles; M/U harbor methylated and unmethylated alleles; 





5637 HT-1376 J82 SCaBER SW780 T24 UM-UC3 
         
NM_001744 camk4 U M U M/U n.a. U U 
NM_004720 LPAR2 U M M/U U U M/U M 
NM_002014 fkbp4 U M M M/U M M M 
NM_002147 hoxB5 M U M U U U M 
NM_000526 krt14 M U M M M M M 
NM_002371 mal M M/U M/U M M M M 
NM_005613 rgs4 M U M U n.a. U U 
NM_003378 vgf M U M M U M U 
NM_003453 ZMYM2 U M U U M M M 
 
 
Table 5. Promoter DNA methylation status of each candidate gene depicted for prostate 
cancer cell lines. Methylation was evaluated by direct sequencing. M, harbor methylated 
alleles; U, harbor unmethylated alleles; M/U harbor methylated and unmethylated alleles; 
n.a., not assessed in this study 
 
RefSeq Gene Symbol DU145 LNCaP PC-3 22Rv1 
      
NM_001744 camk4 M U M U 
NM_004720 LPAR2 M/U M U M 
NM_002014 fkbp4 M/U M M U 
NM_002147 hoxB5 U U U M 
NM_000526 krt14 M M/U M M 
NM_002371 mal M M M U 
NM_005613 rgs4 M U U M 
NM_003378 vgf M M M U 
NM_003453 ZMYM2 U M M M 
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camk4 
 
We examined the promoter DNA methylation status of camk4 by bisulfite sequencing in seven 
bladder and four prostate cancer cell lines (Table 4, 5). camk4 shows promoter methylation in the 
bladder cancer cell lines HT-1376 and SCaBER and the prostate cancer cell lines DU145 and 
PC-3. In order to validate the methylation status in comparison to gene expression, we examined 
camk4 expression by RT-PCR. In cell line SCaBER, treatment with 5-Aza-dC in combination 
with TSA over 3 and 5 days is more effective in regard to re-activation of expression than 
treatment with 5-Aza-dC alone. In cell lines HT-1376 and DU145, 5-Aza-dC alone induces a 
higher degree of re-activation than the combination treatment. In the prostate cancer cell line 
PC-3, 5-Aza-dC treatment over 3 days is effective, while the combination treatment over 5 days 
shows more potent induction of transcript expression. 
 
Promoter DNA hypermethylation associated with gene silencing in primary human bladder and 
prostate tissue results in a significant down-regulation of camk4 expression in the tumor sample 
compared with the corresponding normal tissue sample (Figure 1). Representative bisulfite-
treated genome sequencing of camk4 in the cell line SCaBER is shown in Figure 2. Guanine (G) 
(arrows) represents the complementary base cytosine (C) which was methylated and protected 
on the complementary strand whereas adenine (A) represents the complementary base uracil (U) 
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Figure 1. Expression analysis of camk4 transcripts in bladder and prostate cancer cell lines and 
primary bladder and prostate tissue by RT-PCR. Promoter hypermethylation silences expression of 
camk4 in bladder and prostate cancer cell lines. Re-activation of expression by pharmacologic 
unmasking using 5μM 5-Aza-dC (Aza) treatment alone or in combination with 300 nmol Trichostatin 
A (TSA) over 3 and 5 days. Control (Co) sample including the same volume of DMSO in PBS. The 
camk4 transcript is markedly down-regulated in primary tumor tissue (T) as compared to 





























Figure 2. Representative electropherogram of direct sequencing of camk4 promoter after bisulfite 
treatment of DNA. Guanine (arrows) present after sequencing corresponds to methylcytosine on the 
complementary strand. Bladder cancer cell line SCaBER after treatment with 5-Aza-dC alone or in 
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LPAR2 
 
LPAR2 shows promoter methylation in the bladder cancer cell lines HT-1376, J82, T24 and 
UMUC-3 and the prostate cancer cell lines DU145, LNCaP and 22Rv1 (Table 4, 5). In order to 
evaluate whether methylation is causative for a down-regulation of expression, we determined 
the LPAR2 expression pattern by RT-PCR. In cell lines HT-1376, J82, T24, and LNCaP 
treatment with 5-Aza-dC alone is more effective in regard to re-activation of expression than 
treatment with 5-Aza-dC in combination with TSA over 5 days. In cell lines UMUC3, DU145 
and 22Rv1, the effect of 5-Aza-dC alone is more pronounced after treatment over 3 days. In cell 
line 22Rv1, treatment with 5-Aza-dC in combination with TSA over 5 days is more effective in 
inducing re-activation of LPAR2 expression than the combination treatment. Cell line SCaBER 
does show a re-activation of expression of LPAR2 upon treatment; however, promoter 
methylation cannot be detected (Figure 3). Primary human bladder and prostate tissue shows a 
significant down-regulation of LPAR2 expression in the tumor sample (Figure 3). Representative 
bisulfite-treated genome sequencing of LPAR2 in the cell lines HT-1376, T24, LNCaP and 
22Rv1 are shown in Figure 4. Guanine (G) (arrows) represents the complementary base cytosine 
(C) which was methylated and protected whereas adenine (A) represents the complementary base 
uracil (U) converted from unmethylated C by bisulfite treatment. 
  





























Figure 3. Expression analysis of LPAR2 transcripts in bladder and prostate cancer cell lines and primary 
bladder and prostate tissue by RT-PCR. Promoter hypermethylation silences expression of LPAR2 in 
bladder and prostate cancer cell lines. Re-activation of expression by pharmacologic unmasking using 
5μM 5-Aza-dC (Aza) treatment alone or in combination with 300 nmol Trichostatin A (TSA) over 3 and 
5 days. Control (Co) sample including the same volume of DMSO in PBS. The LPAR2 transcript is 
markedly down-regulated in primary tumor tissue (T) as compared to corresponding normal tissue (N). 
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Figure 4. Representative electropherogram of direct sequencing of LPAR2 promoter after bisulfite 
treatment of HT-1376 DNA. Guanine (arrows) present after sequencing corresponds to methylcytosine on 
the complementary strand. Bladder cancer cell line HT-1376 after treatment with 5-Aza-dC alone or in 
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Figure 5. Representative electropherogram of direct sequencing of LPAR2 promoter after bisulfite 
treatment of T24 DNA. Guanine (arrows) present after sequencing corresponds to methylcytosine on the 
complementary strand. Bladder cancer cell line T24 after treatment with 5-Aza-dC alone or in 





































Figure 6. Representative electropherogram of direct sequencing of LPAR2 promoter after bisulfite 
treatment of LNCaP DNA. Guanine (arrows) present after sequencing corresponds to methylcytosine on 
the complementary strand. Prostate cancer cell line LNCaP after treatment with 5-Aza-dC alone or in 
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Figure 7. Representative electropherogram of direct sequencing of LPAR2 promoter after bisulfite 
treatment of 22Rv1 DNA. Guanine (arrows) present after sequencing corresponds to methylcytosine on 
the complementary strand. Prostate cancer cell line 22Rv1 after treatment with 5-Aza-dC alone or in 
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fkbp4 
 
DNA promoter methylation of fkbp4 is detectable in bladder cancer cell lines HT-1376, J82, 
SCaBER, SW780, T24 and UMUC-3 as well as prostate cancer cell lines DU145, LNCaP 
and PC-3 (Table 4, 5). The expression of fkbp4 in primary human bladder tumor tissue is 
reduced in comparison to matched normal tissue (Figure 8). Representative bisulfite-treated 
genome sequencing of fkbp4 in bladder cancer cell lines HT-1376 after treatment over 5 days 
and UMUC-3 after treatment over 3 days is shown in Figure 9. Guanine (G) (arrows) 
represents the complementary base cytosine (C) which was methylated and protected 
whereas adenine (A) represents the complementary base uracil (U) converted from 













Figure 8. Expression analysis of fkbp4 transcripts in primary human bladder tissue by RT-PCR. The fkbp4 
transcript is down-regulated in primary tumor tissue (T) as compared to corresponding normal tissue (N). 
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Figure 9. Representative electropherogram of direct sequencing of fkbp4 promoter after bisulfite 
treatment of DNA. Guanine (arrows) present after sequencing corresponds to methylcytosine on the 
complementary strand. Bladder cancer cell lines HT-1376 after treatment with 5-Aza-dC alone or in 
combination with TSA over 5 days and UMUC-3 after treatment with 5-Aza-dC alone or in combination 
with TSA over 3 days. 
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hoxB5 
 
hoxB5 shows promoter methylation in the bladder cancer cell lines 5637, J82 and UMUC-3 
as well as in the prostate cancer cell line 22Rv1 (Table 4, 5). In cell lines 5637 and J82, 
5-Aza-dC alone over 3 and 5 days of treatment induces a higher degree of re-activation of 
expression than the combination treatment. In cell line UMUC-3, treatment with 5-Aza-dC 
alone over 3 days results in a more robust expression signal than the treatment in 
combination with TSA. The treatment regimen over 5 days, however, results in a more 
pronounced expression signal when the cell line is treated in combination with TSA. Prostate 
cancer cell lines LNCaP and PC-3 show re-activation of hoxB5 expression upon treatment; 
however, promoter methylation cannot be detected in those cell lines (Table 5). Primary 
human bladder and prostate tissue shows a significant down-regulation of hoxB5 expression 
in the tumor sample (Figure 9). Representative bisulfite-treated genome sequencing of hoxB5 
in bladder cancer cell lines 5637 after treatment over 3 days and UMUC-3 after treatment 
over 5 days is shown in Figure 11. Guanine (G) (arrows) represents the complementary base 
cytosine (C) which was methylated and protected whereas adenine (A) represents the 


























































Figure 10. Expression analysis of hoxB5 transcripts in bladder and prostate cancer cell lines and primary 
bladder and prostate tissue by RT-PCR. Promoter hypermethylation silences expression of hoxB5 in 
bladder and prostate cancer cell lines. Re-activation of expression by pharmacologic unmasking using 
5μM 5-Aza-dC (Aza) treatment alone or in combination with 300 nmol Trichostatin A (TSA) over 3 and 
5 days. Control (Co) sample including the same volume of DMSO in PBS. The hoxB5 transcript is 
markedly down-regulated in primary tumor tissue (T) as compared to corresponding normal tissue (N). 
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Figure 11. Representative electropherogram of direct sequencing of hoxB5 promoter after bisulfite 
treatment of DNA. Guanine (arrows) present after sequencing corresponds to methylcytosine on the 
complementary strand. Bladder cancer cell lines 5637 after treatment with 5-Aza-dC alone or in 
combination with TSA over 3 days and UMUC-3 after treatment with 5-Aza-dC alone or in combination 
with TSA over 5 days. 
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mal 
 
mal displays promoter methylation assessed by bisulfite sequencing in bladder cancer cell lines 
5637, SCaBER, SW780, T24 and UMUC-3 as well as prostate cancer cell lines DU145, LNCaP 
and PC-3 (Table 4, 5). In cell line 5637, treatment with 5-Aza-dC in combination with TSA over 
3 days induces a more pronounced re-activation of expression than treatment with 5-Aza-dC 
alone. Re-activation of mal expression after the treatment regimen over 5 days is more 
significant with 5-Aza-dC alone than with the combination treatment. Cell lines HT-1376 and 
SCaBER also show a higher degree of re-activation with 5-Aza-dC alone. In contrast, 
re-activation of mal expression in cell line T24 cannot be achieved upon treatment over 3 days 
with 5-Aza-dC alone and the signal is less intense in comparison to the combination treatment 
with TSA over 5 days. Combination treatment with TSA over 3 days results in a significant 
up-regulation of expression which is slightly less pronounced after treatment over 5 days. 
Re-activation of mal expression in the prostate cancer cell line DU145 after treatment over 3 
days is more pronounced with 5-Aza-dC alone whereas the treatment regimen over 5 days 
induces a more robust signal with the combination of 5-Aza-dC and TSA. In cell line LNCaP, 
the combination treatment over 3 and 5 days with 5-Aza-dC and TSA is significantly more 
effective than treatment with 5-Aza-dC alone. In cell line PC-3, treatment with 5-Aza-dC alone 
over 3 and 5 days is more effective than in combination with TSA. Primary human bladder and 
prostate tissue shows a significant down-regulation of mal expression in the tumor sample as 
compared to the corresponding normal tissue (Figure 12). Representative bisulfite-treated 





















































Figure 12. Expression analysis of mal transcripts in bladder and prostate cancer cell lines and primary 
bladder and prostate tissue by RT-PCR. Promoter hypermethylation silences expression of mal in bladder 
and prostate cancer cell lines. Re-activation of expression by pharmacologic unmasking using 5μM 5-
Aza-dC (Aza) treatment alone or in combination with 300 nmol Trichostatin A (TSA) over 3 and 5 days. 
Control (Co) sample including the same volume of DMSO in PBS. The mal transcript is markedly down-
regulated in primary tumor tissue (T) as compared to corresponding normal tissue (N). GAPDH 
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Figure 13. Representative electropherogram of direct sequencing of mal promoter after bisulfite treatment 
of DNA. Guanine (arrows) present after sequencing corresponds to methylcytosine on the complementary 
strand. Bladder cancer cell line T24 after treatment with 5-Aza-dC alone or in combination with TSA 
over 5 days. 
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rgs4 
 
Promoter methylation of rgs4 is evident in the bladder cancer cell lines 5637 and J82 and 
prostate cancer cell lines DU145 and 22Rv1 (Table 4, 5). In cell lines 5637 and DU145, 
treatment with 5-Aza-dC over 3 and 5 days induces a more robust expression signal than the 
combination treatment of 5-Aza-dC and TSA over 3 and 5 days. Re-activation of expression is 
more pronounced after treatment over 3 days in comparison to treatment over 5 days. Re-
activation of rgs4 expression in cell line PC-3 is more pronounced after treatment with 5-Aza-dC 
alone than the combination treatment and is more robust after treatment over 3 days than 5 days. 
Cell line PC-3 does not harbor promoter methylation as assessed by bisulfite sequencing. Cell 
line 22Rv1 displays a slight up-regulation of rgs4 expression after treatment with 5-Aza-dC 
alone and in combination with TSA over 3 and 5 days. Primary human bladder and prostate 
tissue shows a gradual down-regulation of rgs4 expression in the tumor sample as compared to 
the corresponding normal tissue (Figure 14). Representative bisulfite-treated genome sequencing 
of rgs4 in cell line 22Rv1 is shown in Figure 15. Guanine (G) (arrows) represents the 
complementary base cytosine (C) which was methylated and protected whereas adenine (A) 

































Figure 14. Expression analysis of rgs4 transcripts in bladder and prostate cancer cell lines and primary 
bladder and prostate tissue by RT-PCR. Promoter hypermethylation silences expression of rgs4 in bladder 
and prostate cancer cell lines. Re-activation of expression by pharmacologic unmasking using 5μM 5-
Aza-dC (Aza) treatment alone or in combination with 300 nmol Trichostatin A (TSA) over 3 and 5 days. 
Control (Co) sample including the same volume of DMSO in PBS. The rgs4 transcript is markedly down-
regulated in primary tumor tissue (T) as compared to corresponding normal tissue (N). GAPDH 
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Figure 15. Representative electropherogram of direct sequencing of rgs4 promoter after bisulfite 
treatment of DNA. Guanine (arrows) present after sequencing corresponds to methylcytosine on the 
complementary strand. Prostate cancer cell line 22Rv1 after treatment with 5-Aza-dC alone or in 
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vgf 
 
Bisulfite sequencing confirms vgf promoter methylation in the bladder cancer cell lines 5637, 
J82, SCaBER, and T24 as well as the prostate cancer cell lines DU145, LNCaP and PC-3 (Table 
4, 5). The vgf transcript is silenced in cell lines harboring promoter hypermethylation. Cell line 
5637 shows extensive suppression of the transcript; only the treatment regimen with 5-Aza-dC in 
combination with TSA over 5 days induces a detectable re-activation of expression. In cell line 
J82, re-activation of vgf expression is more robust upon treatment with 5-Aza-dC in combination 
with TSA over 3 and 5 days; the treatment regimen over 5 days is more effective. In cell line 
SCaBER, only the treatment with 5-Aza-dC in combination with TSA over 3 and 5 days induces 
re-activation of vgf with a more robust signal achieved after treatment over 3 days. In regard to 
prostate cancer cell line DU145 re-activation of vgf expression is more robust after treatment 
with 5-Aza-dC in combination with TSA over 3 and 5 days. The same observation holds true for 
cell lines LNCaP and PC-3 with a stronger signal being achieved after treatment over 5 days. 
 
Primary human bladder tissue shows a significant repression of vgf in the tumor sample as 
compared to the corresponding normal tissue sample. Two prostate tumor tissue samples exhibit 
a down-regulation of vgf in comparison to their matched normal counterparts. However, three 
prostate tumor tissue samples display an up-regulation of vgf in comparison to the matched 
normal samples (Figure 16). Representative bisulfite-treated genome sequencing of vgf in cell 
line PC-3 after treatment over 3 and 5 days is shown in Figure 17. Guanine (G) (arrows) 
represents the complementary base cytosine (C) which was methylated and protected whereas 





































Figure 16. Expression analysis of vgf transcripts in bladder and prostate cancer cell lines and primary 
bladder and prostate tissue by RT-PCR. Promoter hypermethylation silences expression of vgf in bladder 
and prostate cancer cell lines. Re-activation of expression by pharmacologic unmasking using 5μM 5-
Aza-dC (Aza) treatment alone or in combination with 300 nmol Trichostatin A (TSA) over 3 and 5 days. 
Control (Co) sample including the same volume of DMSO in PBS. The vgf transcript is markedly down-
regulated in primary tumor tissue (T) as compared to corresponding normal tissue (N). Three sample pairs 
of primary prostate tissue show an up-regulation of the vgf transcript in the tumor sample. GAPDH 
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Figure 17. Representative electropherogram of direct sequencing of vgf promoter after bisulfite treatment 
of DNA. Guanine (arrows) present after sequencing corresponds to methylcytosine on the complementary 
strand. Prostate cancer cell line PC-3 after treatment with 5-Aza-dC alone or in combination with TSA 
over 3 and 5 days. 
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ZMYM2 
 
Bisulfite sequencing indicates ZMYM2 promoter methylation in the bladder cancer cell lines 
HT-1376, SW780, T24, and UMUC-3 as well as the prostate cancer cell lines LNCaP, PC-3, and 
22Rv1 (Table 4, 5). In cell line HT-1376, treatment with 5-Aza-dC alone and in combination 
with TSA over 3 and 5 days induces an up-regulation of ZMYM2 expression with the strongest 
signal being achieved after treatment with 5-Aza-dC alone over 3 days. In cell line SCaBER, 
treatment with 5-Aza-dC alone over three days results in a significant re-activation of ZMYM2 
expression; after 5 days of treatment, the expression signal induced by 5-Aza-dC alone is more 
robust than the signal achieved after treatment with 5-Aza-dC in combination with TSA. Cell 
line T24 shows a significant re-activation of ZMYM2 expression after treatment with 5-Aza-dC 
alone and in combination with TSA over 3 days; the 5-day treatment regimen results in a 
stronger signal after treatment with 5-Aza-dC alone than the treatment in combination with TSA. 
In cell lines UMUC-3 and LNCaP, the suppression of the ZMYM2 transcript is more profound 
after 5 days and is gradually up-regulated with 5-Aza-dC alone being more effective than in 
combination with TSA. Treatment of the prostate cancer cell line 22Rv1 with 5-Aza-dC alone 
over 3 and 5 days induces a higher degree of ZMYM2 re-activation than the combination 
treatment. ZMYM2 is markedly repressed at the mRNA level in several primary human bladder 
tumor tissue samples as compared to the corresponding normal tissue samples (Figure 18). 
Representative bisulfite-treated genome sequencing of ZMYM2 in the cell line 22Rv1 after 
treatment over 3 days is shown in Figure 19. Guanine (G) (arrows) represents the 
complementary base cytosine (C) which was methylated and protected whereas adenine (A) 
represents the complementary base uracil (U) converted from unmethylated C by bisulfite 
treatment. 
  


































Figure 18. Expression analysis of ZMYM2 transcripts in bladder and prostate cancer cell lines and primary 
bladder tissue by RT-PCR. Promoter hypermethylation silences expression of ZMYM2 in bladder and 
prostate cancer cell lines. Re-activation of expression by pharmacologic unmasking using 5μM 5-Aza-dC 
(Aza) treatment alone or in combination with 300 nmol Trichostatin A (TSA) over 3 and 5 days. Control 
(Co) sample including the same volume of DMSO in PBS. The ZMYM2 transcript is markedly down-
regulated in primary tumor tissue (T) as compared to corresponding normal tissue (N). GAPDH 
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Figure 19. Representative electropherogram of direct sequencing of ZMYM2 promoter after bisulfite 
treatment of DNA. Guanine (arrows) present after sequencing corresponds to methylcytosine on the 
complementary strand. Prostate cancer cell line 22Rv1 after treatment with 5-Aza-dC alone or in 
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Methylation-specific PCR 
 
Conventional MSP analysis for LPAR2, hoxB5, rgs4, and ZMYM2 in cell lines is shown in Figure 
20. Methylation of LPAR2 is evident in bladder cancer cell lines J82, T24, UMUC-3 and prostate 
cancer cell lines LNCaP and 22Rv1. hoxB5 is methylated in bladder cancer cell lines 5637, 
HT-1376, J82, and UMUC-3 as well as the prostate cancer cell line 22Rv1. Promoter DNA 
methylation of rgs4 could be confirmed by MSP in bladder cancer cell lines 5637 and J82 as 
well as prostate cancer cell lines DU145 and 22Rv1. ZMYM2 is methylated in bladder cancer cell 





































Figure 20. Methylation-specific PCR analysis of a series of bladder and prostate cancer cell lines. 
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Quantitative Real-Time Methylation-specific PCR 
 
To determine the frequency fkbp4 and vgf methylation in a larger set of bladder tumor and 
matched normal tissue samples (n = 19), quantitative MSP was applied. fkbp4 was methylated in 
6 of 19 (31.6 %) bladder tumors vs. 3 of 19 (15.8 %) matched normal samples (cut-off 0). vgf 
was methylated in 17 of 19 (89.5 %) bladder tumors vs. 13 of 19 (68.4 %) matched normal 

























Figure 21. Quantitative MSP of 19 primary bladder tumors and matched normal human bladder tissue 
samples. Scatter plot of quantitative MSP analysis of fkbp4 and vgf. The relative level of methylated 
DNA for each gene in each sample was determined as a ratio of MSP for the amplified gene to β-
actin, multiplied by 1000 for easier tabulation [(average value of duplicates of gene of interest / 
average value of duplicates of β-actin)  1000]. The samples were categorized as methylated or 
unmethylated based on detection of methylation above a threshold set for each gene. This threshold 
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Discussion 
 
The DNA methylome opens venues to identify potentially powerful diagnostic biomarkers. 
In human colorectal cancer, hypermethylation is estimated to be one order of magnitude more 
frequent than gene mutation (Schuebel et al., 2007). 
 
The genes discussed in this study have been identified based on a modification of the methylated 
gene discovery algorithm. This gene filtering approach starts with a reactivation filter, followed 
by a broad analysis of genome-wide promoter alignment assisted by the Database of 
Transcription Start Sites. A CGI is defined as a region of minimal 200 bp, a GC content larger 
than 50%, and a CpGobserved/CpGexpected ratio > 0.60. In order to include shorter patterns 
associated with known cancer-specific methylation, a subsequent computational promoter 
analysis aims to identify discriminating sequence patterns between two different functional 
classes of CGI-containing promoters (Hoque et al., 2008). 
 
5-Aza-dC functions as a DNA methyltransferase inhibitor and shows substantial potency in 
reactivating epigenetically silenced TSGs in vitro. It is an established drug for epigenetic cancer 
therapy, and the clinical effects are due to epigenetic reprogramming and the induction of 
apoptosis. Four candidate transporter protein families mediate the cellular uptake of the 
azanucleoside: equilibrative uniporters (SLC29A family), substrate exchange transporters 
(SLC22 and SLC15 family), concentrative transporters (SLCA28 family), and ATP-dependent 
exporters (ABC family). After cellular uptake, the compound is being phosphorylated by 
deoxycytidine kinase into 5-aza-dC-5’-triphosphate, the active nucleotide for DNA methylation 
inhibition. 5-aza-dC-5’-triphosphate is being incorporated into DNA, where azacytosine 
substitutes for cytosine with a substitution rate being as high as 10%. One theory for the 
induction of de-methylation is represented by the covalent trapping paradigm: the covalent bond 
between the carbon-6-atom of the cytosine ring and the methyltransferase inhibits enzyme 
function and leads to degradation of trapped methyltransferases. The drug has also been shown 
to induce proteasomal targeting of the enzyme (Stresemann and Lyko, 2008). 
 
TSA is a specific, non-competitive inhibitor of HDACs and causes hyperacetylation of core 
histones. The interchangeable effects of 5-aza-cytidine and TSA indicate an interaction between 
hypoacetylation and the methylation status (Selker, 1998). While CGI methylation is dominant 
over histone deacetylase activity in maintaining a transcriptionally silent state in cancer, histone 
deacetylase activity comes into play when DNA methylation is being experimentally decreased. 
5-Aza-dC and TSA act synergistically in regard to re-expression of silenced genes in cancer 
(Cameron et al., 1999). Pharmacological stimulation of histone acetylation by TSA induces 
replication-independent de-methylation (Cervoni and Szyf, 2001), and an initial RNA 
transcription by RNA polymerase II is a prerequisite for active DNA de-methylation (D’Alessio 
et al., 2007). 
 
An increase in de novo methylation of CGIs correlates with invasion and progression of bladder 
cancer (Salem et al., 2000). DBCR1 within the candidate tumor suppressor region at 9q32-q33 
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has been shown to be silenced by promoter hypermethylation (Habuchi et al., 1998). 
Hypermethylation of APC, p14, RASSF1A (Dulaimi et al., 2004), and the apoptosis-associated 
gene DAPK (Friedrich et al., 2004) is detectable in urine sediments of cancer patients. CpG-
island hypermethylation of p16
Ink4a
 and TPEF/HPP1 and hypermethylation of the miRNA 
miR-127 are established in bladder cancer (Esteller, 2008). 
 
Inactivation of the tumor suppressor gene PTEN/MMAC1 is found in advanced prostate cancer 
(Cairns et al., 1997). Genes affected by epigenetic aberrations in prostate cancer include classic 
and putative tumor suppressor genes like RASSF1A, KAI1, inhibin-α, and DAB2IP as well as 
genes playing important roles in hormonal response, cell cycle control, tumor cell invasion/tumor 
architecture, DNA damage repair, signal transduction and inflammatory response (Li et al., 
2005). Early aberrant promoter methylation in prostate tumorigenesis has been identified for 
RARβ2 (Jerónimo et al., 2004), cyclin D2 (Padar et al., 2003), GSTP1 (Jerónimo et al., 2004), 
and MCAM (Liu et al., 2008). Current methylation profiling encompasses GSTP1, APC, 
RASSF1, MDR1, and MGMT; however, prostatic intraepithelial neoplasia (PIN) and prostate 
cancer exhibit comparable methylation levels (Kang et al., 2004; Yegnasubramanian et al., 
2004). Promoter methylation of the potential marker ssDNA-binding protein 2 allows a 
differentiation between benign prostatic hyperplasia (BPH), PIN and prostate cancer and 
correlates with tumor stage (Liu et al., 2008). 
 
Polycomb group (PcG) proteins are transcriptional repressors that maintain cellular identity by 
epigenetic regulation of chromatin (Ringrose and Paro, 2004). The polycomb repressive complex 
(PRC) 2 protein EZH2 undergoes gene amplification and induces transcriptional repression in 
metastatic prostate cancer (Varambally et al., 2002). The existence of global H3 and H4 histone 
modifications over large regions of chromatin including coding regions and non-promoter 
sequences demonstrates the molecular heterogeneity in prostate cancer. These aberrant 
modification patterns are predictive of clinical outcome (Seligson et al., 2005). Recurrent gene 
fusions of 5’ genomic regulatory elements and Ets transcription factors are detectable in 
approximately 50% of prostate cancers from serum prostate-specific antigen-screened patient 
cohorts. TMPRSS2-ERG represents the most frequent fusion; additional fusion partners are 
ETV1, ETV4, and ETV5. Due to the induction of plasminogen activation and matrix 
metalloproteinase pathways ERG overexpression has been linked to the acquisition of 




The presence of methylation in bladder cancer cell lines HT-1376 and SCaBER and prostate 
cancer cell lines DU145 and PC-3 corresponds to the expression data. Primary human bladder 
and prostate tumor tissue shows a significant down-regulation of camk4. Human camk4 gene 
maps to a region that is rich in genes regulating cell growth (Chandrasekharappa et al., 1990). 
CaMKIV-deficient thymocytes exhibit impaired positive selection and defective Ca
2+
-dependent 
gene transcription (Raman et al., 2001). CaMKIV has been implicated in transcriptional 
regulation in T-lymphocytes (Anderson et al., 1997), neurons (Bito et al., 1996) and male germ 
cells (Westphal et al., 1998). In the mouse testis, CaMKIV is expressed in spermatids and 
targeted to chromatin and the nuclear matrix (Wu and Means, 2000). 
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A core function of CaMKIV is Ca
2+
-dependent transcriptional activation (Corcoran and Means, 
2001). CaMKIV regulates cAMP response element-binding protein (CREB) (Matthews et al., 
1994; Sun et al., 1994), p300/CREB-binding protein (Chawla et al., 1998), myocyte-specific 
enhancer factor 2 (Blaeser et al., 2000) and HDACs (McKinsey et al., 2000). CaMKIV also has a 
regulatory function in both MAPK and cAMP pathway (Enslen et al., 1994; 1996; Wayman et 
al., 1996). camk4 has been implicated in the regulation of cAMP response element (CRE)-
dependent transcription. Transcriptional activation of CREB/CRE-mediated signaling pathway is 
initiated by the phosphorylation of CREB at Ser
133
. In vitro, inhibition of CaMKIV activity by 
transfection significantly reduces nuclear CREB phosphorylation and CRE-dependent 
transcription in neurons (Bito et al., 1996). Constitutively active CaMKIV increases the activity 
of CREB binding protein, thereby stimulating CRE-dependent transcription (Chawla et al., 
1998). Activation of immediate-early genes such as c-fos depends on CREB phosphorylation 
(Sheng and Greenberg, 1990). By using conditional transgenic mice with a dominant-negative 
form of CaMKIV it could be shown that the inhibitory effect is specifically related to Ca
2+
-
induced CREB phosphorylation, activation of CRE-dependent transcription in the adult mouse 
hippocampus and c-Fos expression (Kang et al., 2001). 
 
A transcriptional downregulation of camk4 by methylation might therefore affect multiple 
signaling pathways, with MAPK, cAMP and CREB pathways being the most relevant. The 
interaction with HDACs is of particular interest because of the crucial involvement of those 




The downregulation of the fkbp4 transcript in primary bladder tissue could be confirmed by 
QMSP. FKBP4 transcriptionally down regulates the activity of interferon regulatory factor-4 in 
immune cells (Mamane et al., 2000) and heat shock factor-1 in HeLa cells (Guo et al., 2001). It 
is expressed at high levels in breast cancer cell lines (Ward et al., 1999). Promoter constructs 
with only 143 bp of the upstream sequence maintain high activity in breast cancer cells and 
contain a CAAT box motif as well as consensus binding sites for the transcription factors Sp1, 
heat-shock factor and MYC-MAX (Scammell et al., 2003) which may indicate the induction of 
fkbp4 mRNA in cancer cells expressing myc. The basal expression of human α1d-adrenergic 
receptors is regulated by Sp1-dependent binding of two promoter-proximal GC boxes. Sp1 
binding closely correlates with expression of the endogenous gene, and promoter methylation-
dependent silencing has been shown to disrupt Sp1 binding resulting in repression of basal 
α1d-adrenergic receptor expression (Michelotti et al., 2007). 
 
HSP 90 binding immunophilins link p53∙HSP90 heterocomplexes to dynein thereby promoting 
retrograde nuclear translocation of the tumor suppressor protein p53. The linkage of the 
immunophilin to the dynein motor complex is accomplished by the dynamitin component of the 
dynactin complex. By virtue of its PPIase domain, FKBP4 binds directly to dynamitin 
(Galigniana et al., 2004). 
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The interaction between the PPIase domain I of FKB4 and Atox1, a copper-binding 
metallochaperone transferring copper to Menkes Disease Protein and Wilson Disease Protein 
indicates that FKBP4 positively regulates the copper efflux machinery in mammalian cells 
(Sanokawa-Akakura et al., 2004). Cancer can be accompanied by a disruption of the cellular 
copper homeostasis (Tapiero et al., 2003). 
 
Based on the important functions of FKBP4 in the regulation of Ca
2+
 reabsorption and direct 
modulation of intracellular Ca
2+
 homeostasis, fkbp4 repression as a consequence of promoter 
methylation might severely affect Ca
2+
 metabolism. Furthermore, binding to HSP90 could be 
diminished. Downregulation of fkbp4 might also result in an up-regulation of CKII-activity with 




The hypermethylation found in bladder cancer cell lines 5637, J82, and UM-UC3 is significantly 
associated with reduced expression confirmed by RT-PCR as well as MSP. The methylation in 
prostate carcinoma cell line 22Rv1 is consistent with MSP. The finding of reduced expression in 
prostate cancer cell lines LNCaP and PC-3 could not be shown to correlate with hyper-
methylation. It is conceivable that additional regulatory mechanisms of repression other than 
methylation and cell line inherent factors come into play. 
 
hoxB5 Hox expression is altered (Alonso Varona et al., 1996) and various genes in the HOXA 
and HOXD clusters are methylated in lung cancer (Shiraishi et al., 2002). By using CGI tiling 
arrays in combination with the methylated CGI recovery assay, Rauch et al. (2007) found that 
the four gene clusters on chromosomes 2, 7, 12, and 17 are preferential targets for DNA 
methylation in lung cancer cell lines and early-stage lung cancer. The lack of methylation at 
CpG-rich sequences in the HOXA cluster correlates with the presence of the active chromatin 
mark, H3K4me3. HOXA7- and HOXA9-associated CGIs represent frequent methylation targets 
in stage 1 primary squamous cell carcinomas of the lung. 
 
Aberrant expression of homeobox genes has been shown in hematological malignancies and 
solid tumors (Grier et al., 2005). The mixed lineage leukaemia (MLL) gene, the human homolog 
of Drosophila trithorax, is rearranged in human leukemias and regulates target Hox gene 
expression through direct binding to Hox promoter sequences. The MLL SET domain is a 
H3K4me3-specific methyltransferase (Milne et al., 2002). By a small-array real-time HOX 
quantitative PCR, Thompson et al. (2003) reported a global down-regulation of 26 HOX genes, 
including HOXB5 in acute promyelocytic leukemia and proposed a model linking HOX gene 
expression to the PML-retinoic acid receptor α repressor complex. 
 
HOXB5 and HOXB9 are down regulated in renal cancer (Cillo et al., 1992) and HOXB13 is 
methylated in 30% of renal cell carcinomas (Okuda et al., 2006). The HOXA gene cluster is 
methylated in breast cancer (Novak et al., 2006). HOXA9 and HOXB5 are hypermethylated in 
ovarian carcinoma (Wu et al., 2007). 
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In human prostate cancer, overexpression of HOXC8 correlates with loss of tumor differentiation 
(Waltregny et al., 2002) indicative of the acquisition of invasiveness and metastatic disease. 
Non-seminomatous testicular germ cell tumors display a high frequency of HOXA9 promoter 
methylation, while HOXB5 is methylated at a lower frequency (Lind et al., 2006). 
 
A link of HOX gene expression with apoptosis is demonstrated by the coordinate loss of p53 and 
HOXA5 mRNA and protein expression in human breast cancer cell lines and tumors. The 
HOXA5 promoter region was methylated in p53-negative breast tumor specimens and transient 
transfection of Hox/HOXA5 could be shown to activate the p53 promoter (Raman et al., 2000). 
Apoptosis induced by HOXA5 expression is mediated by caspases 2 and 8 and by sensitization to 
tumor necrosis factor α (Chen et al., 2004). 
 
HoxB5 is a potent early transcriptional regulator of the differentiation of angioblasts and mature 
endothelial cells from their mesoderm-derived precursors. Using a yeast one-hybrid system, 
hoxB5 could be identified as the transcription factor binding the cis-acting element in the first 
intron of the receptor 2 for vascular endothelial growth factor (VEGFR-2), flk1. Overexpression 
of hoxB5 led to expansion of flk1
+
 angioblasts and increased the number of mature endothelial 
cells, which form primitive blood vessels and express platelet-endothelial cell adhesion molecule 
(Wu et al., 2003). 
 
Highly conserved noncoding elements in the mammalian genome cluster within regions 
encoding developmentally relevant transcription factors. They are characterized by a specific 
modification pattern, termed “bivalent domains”, characterized by extended regions of 
H3K27me3 harboring smaller regions of H3K4me3. In regard to the Hox regions, these bivalent 
domains are large and overlap multiple transcription start sites of transcription factors (Bernstein 
et al., 2006). 
 
Homeobox genes are classic targets of Polycomb complexes. Stem cell Polycomb target genes 
are susceptible to hypermethylation and subsequent transcriptional repression in cancer 
(Widschwendter et al., 2007). H3K27me3 is a marker for repressive chromatin and interacts with 
PRC 2 (Cao et al., 2002). H3K27me3 is enriched at genes occupied by components of PRC1 and 
PRC2 associated with modified nucleosomes in a repressed transcriptional state. Depletion of the 
PRC2 component EED (embryonic ectoderm development) in murine ES cells induces 
de-repression of PcG target genes including Hox and loss of association of PRC1 at target genes 
supporting the relevance of an intact PRC2 complex and/or its histone methyl mark H3K27me3 
for PRC1 binding reactions (Boyer et al., 2006). The expression of the catalytically active 
component of PRC2, enhancer of zeste 2 (EZH2) is increased in tumor tissue and premalignant 
lesions. EZH2 associates with DNMT activity in somatic cells (Viré et al., 2006). The PRC2 
subunit SUZ12 (Suppressor of zeste 12) is required for histone methyltransferase activity and 
silencing of the EED-EZH2 complex (Bracken et al., 2006). PRC1 possesses a H2A-K119 
ubiquitin E3 ligase activity associated with repression of Hox genes (Cao et al., 2005). 
 
The down regulation of Polycomb target genes SUZ12, EED, and trimethylated H3K27 is 
associated with ES cell identity and correlates with a poor differentiation state and aggressive 
tumor behavior. The ES signature is predictive of poor outcome. Human high-grade bladder 
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carcinoma shows an ES-like gene set enrichment pattern (Ben-Porath et al., 2008). Over-
expression of EZH2 in metastatic prostate cancer leads to trimethylation of H3K27 resulting in 
repression of target gene expression. Yu et al. (2007) propose a set of Polycomb repression 
signature genes that might encode suitable biomarkers for metastatic prostate cancer at early 
stages. In regard to the epigenetic programming of the prostate cancer cell line PC-3, DNA 
hypermethylation has the potential to replace Polycomb-based repression, possibly reducing 




Promoter methylation of LPAR2 in bladder cancer cell lines HT-1376, J82, T24, and UM-UC3 as 
well as prostate cancer cell lines DU145, LNCaP and 22Rv1 has been evaluated by bisulfite 
DNA modification and MSP. These data correspond to transcriptional repression demonstrated 
by RT-PCR. Primary human bladder and prostate tumor samples indicate LPAR repression with 
a more pronounced effect in bladder tissue. One major effect of an epigenetic silencing of 
LPAR2 might be the diminished transduction of Ca
2+
 mobilization through pertussis toxin-
sensitive Gi and Gq proteins. 
 
A guanine nucleotide deletion in the ORF causing a frame shift mutation near its C-terminal 
coding region has been described for a human LPAR2 cDNA clone (Contos and Chun, 2000). 
LPA induces tumor cell invasiveness (Imamura et al., 1993; Stam et al., 1998), activates ovarian 
and breast cancer cells (Xu et al., 1995) and is detectable in high concentrations in the plasma of 
ovarian cancer patients (Xu et al., 1998). LPA both stimulates and inhibits proliferation (Tigyi et 
al., 1994), and has been shown to protect T cells from apoptosis in association with suppression 
of Bax (Goetzl et al., 1999). Human blood CD4
+
 T cells constitutively express LPAR2, and 
inhibition of stimulated IL-2 secretion by LPA in CD4
+
 T cells confirms LPAR2 as a transducer 




With the exception of prostate cancer cell line 22Rv1 mal displays consistent promoter 
methylation assessed by bisulfite sequencing in all cancer cell lines assessed in this study. These 
findings are associated with reduced gene expression in bladder cancer cell lines 5637, HT-1376, 
SCaBER, and T24 as well as prostate cancer cell lines DU145, LNCaP, and PC-3 as well as 
primary bladder and prostate tumor tissue. In esophageal cancer mal has been shown to suppress 
motility, invasion and tumorigenicity in vivo by the induction of apoptosis via the Fas signaling 
pathway (Mimori et al., 2003). Loss of mal expression in precancerous lesions of the esophagus 
could be shown in a multi-step carcinogenic rat model for esophageal cancer and in human 
dysplastic lesions adjacent to cancer sites. mal expression correlates with an up-regulation of 
keratin 8, 10, 18 as well as neurotrophic tyrosine kinase receptor, type 2 and caspase 6. 
mal transfection exerts an anti-tumor effect with differentiation of the esophageal epithelium 
(Mimori et al., 2006). Based on the promoter methylation of keratin 14 (Table 2), we propose 
a synergistic down regulation by promoter methylation of mal and keratin 14. 
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Downregulation of mal in cervical squamous cell cancer has been shown not to be the result of 
allelic loss or somatic mutation (Hatta et al., 2004). By combining complementary DNA 
microarray data with in silico genetic and functional analysis, cancer-specific epigenetic 
silencing of mal has been identified in colon cancer (Mori et al., 2006). Promoter hyper-
methylation of mal was found in human cancer cell lines from breast, kidney, ovary, and uterus 
as well as in benign and malignant colorectal tumors and has been proposed as a diagnostic 




Promoter methylation of rgs4 is present in bladder cancer cell lines 5637 and J82 as well as 
prostate cancer cell lines DU145 and 22Rv1 as assessed by bisulfite modification and MSP. Cell 
lines 5637, DU145, PC-3 and 22Rv1 show an up-regulation of expression after treatment. In the 
adenocarcinoma, stage IV cell line PC-3 additional regulatory mechanisms other than 
methylation might be operative. Primary bladder and prostate tumor tissue reveals a down-
regulation of this gene. By virtue of their GAP activity, RGS proteins affect effector protein 
activation by hormones (Zeng et al., 1998; Xu et al., 1999) and RGS4 may induce oscillations of 
intracellular Ca
2+
 concentration in dependence on G-coupled agonist activity (Popov et al., 
2000). RGS proteins also reconstitute the rapid gating kinetics of Gβγ-activated inwardly 
rectifying K
+
 channels (Doupnik et al., 1997). Based on their GAP activity, RGS proteins 





activity. Functional down-regulation of rgs4 by promoter methylation may therefore imply 
complex intra- and intercellular disturbances which are not yet defined in the context of cancer 




Promoter hypermethylation of vgf is evident in bladder cancer cell lines 5637, J82, SCaBER, and 
T24 as well as prostate cancer cell lines DU145, LNCaP and PC-3. These findings are consistent 
with vgf upregulation following pharmacologic unmasking. A significant down-regulation is 
present in primary bladder tumor samples as assessed by RT-PCR and QMSP. In prostate tissue, 
we detected a significant down-regulation in two sample pairs, while three other sample pairs 
displayed an up-regulation of vgf. These data are reconcilable considering that the expression of 
vgf in malignant cells may change as neoplastic progression occurs. vgf down-regulation may 
represent an early event, whereas vgf upregulation in the tumor sample may be a later event 
inherent to tumourigenicity and angiogenesis. Flk1/VEGFR-2 represents the earliest set of 
angioblast markers. 
 
CREB binding protein (CBP) is a histone acetyltransferase (HAT) (Ogryzko et al., 1996) that 
interacts with nerve growth factor-inducible protein A (NGF1-A) (Silverman et al., 1998). 
NGF1-A participates in epigenetic programming of glucocorticoid receptor (GR) gene 
expression. In the rat, activation of gene transcription through the exon 17 GR promoter has been 
shown to be dependent on the methylation status of the 5’ CpG site within the NGF1-A 
consensus sequence. De-methylation is accompanied by increased CBP association with the exon 
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17 GR promoter. NGF1-A overexpression has been found to recruit CBP to the exon 17 sequence 
resulting in an increase in histone acetylation (Weaver et al., 2007). 
 
NGF promotes neuronal survival via CREB-dependent Bcl-2 expression (Riccio et al., 1999). 
The intrinsic HAT activity of the nuclear receptor coactivator CBP/p300 and the histone 
methyltransferase activity of the coactivator-associated arginine methyltransferase 1 (CARM1) 
act synergistically in regard to histone modification. Methylation of the CBP/p300 KIX domain 
by CARM1 inhibits CREB activation by preventing the interaction between KIX and the kinase 
inducible domain of CREB. The inhibition of CBP and CREB association by CARM1 is 
dependent on the histone methyltransferase activity of CARM1. Subsequent inhibition of Bcl-2 




ZMYM2 shows promoter methylation in bladder cancer cell lines HT-1376, SW780, T24, and 
UM-UC3 as well as prostate cancer cell lines LNCaP, PC-3, and 22Rv1 as assessed by bisulfite 
modification and MSP. This parallels an up-regulation after treatment in cell lines HT-1376, 
T24, UM-UC3, LNCaP and 22Rv1. The up-regulation following treatment of the squamous cell 
carcinoma cell line SCaBER might be caused by an additional layer of transcriptional repression. 
Primary human bladder tissue shows a down-regulation in the tumor sample. 
 
Stimulated FGFR1 activates an array of downstream signaling molecules such as the STAT 
family of transcription factors, phosphatidylinositol 3-kinase (PI3K), phospholipase C-γ (PLC-γ), 
and MAPK (Hart et al., 2000; Ryan and Gillespie, 1994). Expression of ZNF198-FGFR1 results 
in increased tyrosine phosphorylation of STAT1 and STAT5 in Ba/F3 cells (Smedley et al., 
1999). The activation of STAT1, 3, and 5 promotes the induction of STAT specific genes and 
this specificity has been compared to the signaling capacity of IL-6-type cytokines (Baumann et 
al., 2003). Expression of ZNF198-FGFR1 in primary murine hematopoietic cells induces a 
myeloproliferative syndrome in mice that recapitulates the human phenotype. The activation of 
the downstream effectors PLC-γ, STAT5, and PI3K/AKT requires the proline-rich domains of 
ZNF198 in vivo. Deletion of the proline-rich domain results in loss of tyrosine kinase activity, 
and transforming activity in Ba/F3 cells. A small-molecule selective tyrosine kinase inhibitor, 
N-benzoyl-staurosporine (PKC412) prevents tyrosine autophosphorylation as well as 
phosphorylation of the signaling intermediates PLC-γ and PI3K, thereby significantly reducing 
the proliferation of ZNF198-FGFR1 transformed Ba/F3 cells and prolonging survival in a murine 
bone marrow transplant assay (Chen et al., 2004). 
 
ZNF198 localizes to punctate nuclear structures (Baumann et al., 2003) in which ZNF198 is 
present in a protein complex with promyelocytic leukemia nuclear bodies (Kunapuli et al., 2006) 
as well as other nuclear structures (Kasyapa et al., 2005). The atypical zinc finger domain 
promotes protein-protein interactions. It interacts with post-replication DNA repair-associated 
HHR6A/6B and RAD18 proteins (Kunapuli et al., 2003). Initial mass spectroscopy analysis 
identified the RNA splicing and maturation proteins SFPQ (PSF), PTBP1, hnRNPA2/B1, and 
hnRNPH3 as interacting partners of ZNF198 (Kasyapa et al., 2005). It also binds to UBTF, 
a nuclear trans-activation factor in rDNA transcription (Ollendorf et al., 1999). 
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In yeast two-hybrid screens, ZNF198 could be shown to bind to UBE2A/B (Kunapuli et al., 
2003), small ubiquitin related modifier-1 protein (Kunapuli et al., 2006), the MH2 domain of 
Smad 3 suggesting a role as a transcriptional co-factor in transforming growth factor-β signaling 
(Warner et al., 2003), and to CCAAT-enhancer binding protein-ε (C/EBPε), a nuclear 
transcription factor regulating terminal myeloid differentiation. ZNF198 as well as a protein 
inhibitor of activated STAT1 modulate the function of C/EBPε in mediating gene transcription 
during myelopoiesis. UBE2A/B recruits RAD18 in DNA repair reactions. While UBE2A/B is 
capable of interacting with ZNF198-FGFR1, RAD18 has lost this capacity resulting in an 
increased sensitivity to UV-B irradiation (Chih et al., 2004). 
 
ZNF198-FGFR1 protein localizes to the cytoplasm and has been shown to induce expression of 
protease inhibitors, with plasminogen-activator inhibitor type 2 having a prominent role in 
stabilizing the protein as a central mechanism in oncogenicity (Kasyapa et al., 2006). HSPA1A, 
a member of the HSP70 gene family, has also been found in a protein complex with ZNF198 and 
maintains the stability and function of the fusion protein. Exogenous expression of the ZNF198-
FGFR1 fusion kinase gene as well as ZNF198 is accompanied by a significant increase in HSP70 
mRNA levels. Using a specific inhibitor of HSP70 transcription it could be shown that the 
chaperone protein HSPA1A stabilizes ZNF198 in the nucleus and is a prerequisite for specific 
functions of ZNF198-FGFR1 such as STAT3 phosphorylation (Kasyapa et al., 2007). 
 
The activation of the AKT and MAPK prosurvival signaling pathways results in an increased 
phosphorylation of the AKT targets FOXO3a and BAD which subsequently sequestered to 
14–3-3 phosphoserine/threonine-binding proteins to prevent apoptosis. Dissociation of FOXO3a 
from 14–3-3τ isoform binding by a peptide-based competitive antagonist induced apoptosis in 
transformed hematopoietic cells. FOXO3a release is accompanied by restoration of its nuclear 
localization and by up-regulation of Bim1 and p27
kipI
 (Dong et al., 2008). Epigenetic inactivation 
of the 14–3-3σ isoform has been shown in breast, skin, and prostate carcinoma (Dougherty and 
Morrison, 2004). 
 
The identification of these genes by the candidate gene approach confirms the effectiveness of 
this method in regard to the characterization of organ- and cancer-specific methylation. The 
methylation profile in conjunction with expression analysis has been tested in a panel of eight 
genes. The aim of this study is the development of a panel of methylated loci specific for 
genitourinary cancer. Further functional studies are warranted in order to elucidate the molecular 
mechanisms of these genes in bladder and prostate cancer. These potentially important targets of 
transcriptional silencing in cancer could serve as biomarkers for screening purposes in genito-
urinary and potentially other cancers as well. 
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Supplemental Table S1. Primers used for Bisulfite Sequencing 
 
RefSeq Gene Symbol F (5' - 3') (position at promoter) R (5' - 3') (position at promoter) Amplicon size (Nucleotide range) Annealing temperature
NM_001744 camk4 TTTTGATAGAGGATGGTTGGTTAGT ( 441 to 465) AAACTTAAAAAAAACACAAAAACCC ( 682 to 706) 266 bp ( 441 to 706) Step down 56-48°C
NM_004720 LPAR2 GGGTAGGGTTTTTTTAGGTGGT ( 937 to 958) AAACCTCACCTAAACCTCCAATC ( 1111 to 33) 197 bp ( 937 to 1133) Step down 56-48°C
NM_002014 fkbp4 TTTTTTTTAAGTAGGGAAGGGTTT ( 220 to 197) TAATTCTTACCTCCTTCTAACTACC ( 5 to 29) 250 bp ( 220 to 29) Step down 56-48°C
NM_002147 hoxb5 GTAGGGAGTTAGTAGGGAGGTAGT ( 674 to 697) AAATTAACTTTAACCTCTAAACAAAA ( 757 to 782) 109 bp ( 674 to 782) Step down 56-48°C
NM_000526 krt14 TAAGGGGAATGGAAAGTGTTAGAT ( 930 to 953) CAAAAACCCTTCATAAAACTAAAAAAA ( 1088 to 1114) 185 bp ( 930 to 1114) Step down 56-48°C
NM_002371 mal TTTAATTGGGGTTAGATGTAGGTAG ( 1391 to 1415) AAAAACTTTAAAAAACCAAAAAAAA ( 1645 to 1669) 279 bp ( 1391 to 1669) Step down 56-48°C
NM_005613 rgs4 TAGAGGGAGATAGAGGAGTTGGTATT ( 904 to 929) ACAAACCTACAAACCCTTTACACAT ( 1125 to 1149) 246 bp ( 904 to 1149) Step down 56-48°C
NM_003378 vgf AAGATTTATTTATTTGTTTTTGT ( 330 to 352) ACCAATAAAAACTCAATACT ( 512 to 531) 202 bp ( 330 to 531) Step down 56-48°C




Supplemental Table S2. Primers used for RT-PCR 
 
RefSeq Gene Symbol F (5' - 3') (position at coding sequence) R (5' - 3') (position at coding sequence) Amplicon size (Nucleotide range) Annealing temperature
NM_001744 camk4 TCCATCGTGATCTCAAACCA (482 – 501) CAGGTCCATAGGCACAACCT (642 – 661) 180 bp (482 – 661) 58°C
NM_004720 LPAR2 TTGTCTTCCTGCTCATGGTG (596 – 615) TGCAGGACTCACAGCCTAAA (795 – 814) 219 bp (596 – 814) 58°C
NM_002014 fkbp4 GATCGTGTCTTGGCTGGAAT (885 – 904) CTTCTCGTTGTTGCTGTCCA (1043 – 1062) 178 bp (885 – 1062) 59°C
NM_002147 hoxb5 GCAGACTCCGCAAATATTCC (513 – 532) TGTCCTTCTTCCACTTCATGC (737 – 757) 245 bp (513 – 757) 59°C
NM_002371 mal GGGTGATGTTCGTGTCTGTG (252 – 272) ACACCATCTGGGTTTTCAGC (540 – 559) 308 bp (252 – 559) 60°C
NM_005613 rgs4 AGTCCCAAGGCCAAAAAGAT (322 – 341) GACGGGTTGACCAAATCAAG (523 – 542) 221 bp (322 – 542) 59°C
NM_003378 vgf GACCCTCCTCTCCACCTCTC (160 – 179) ACCGGCTCTTTATGCTCAGA (325 – 345) 186 bp (160 – 345) 62°C




Supplemental Table S3. Primers and Probes used for MSP and QMSP 
 
RefSeq Gene Symbol F (5' - 3')  (position at promoter) R (5' - 3')  (position at promoter) Probe (6FAM 5' - 3'TAMRA) Amplicon size (Nucleotide range) Annealing temperature
NM_004720 LPAR2  M GTTTTTCGCGTTTTTTTAGTAATTC ( 984 to 1008) TCACCTAAACCTCCAATCACG ( 1108 to 1128) 145 bp ( 984 to 1128) 58.0°C
LPAR2  U TTTTTGTGTTTTTTTAGTAATTTGT ( 986 to 1010) TCACCTAAACCTCCAATCACAC ( 1107 to 1128) 143 bp ( 986 to 1128) 56.1°C
NM_002014 fkbp4  M GTTCGTGGTGACGGTCGGTTTCGGG (–163 to –141) ATCCGCTACGCCTACGACG (–92 to –72) CAAACTACGAAATAACAATAACGACGC (–134 to –106)   92 bp (–163 to –72) 58.0°C
NM_002147 hoxb5  M GTAGGGAGTTAGTAGGGAGGTAGTC ( 674 to 698) TTTAACCTCTAAACAAAACGCG ( 753 to 774) 101 bp ( 674 to 774) 59.0°C
hoxb5  U TAGGGAGTTAGTAGGGAGGTAGTTGT ( 675 to 700) ACTTTAACCTCTAAACAAAACACACC ( 751 to 776) 102 bp ( 675 to 776) 63.0°C
NM_005613 rgs4  M GATAGAGGAGTTGGTATTGTAGAGC ( 912 to 936) CGACAAAAAAAACTATAACTTCGAC ( 1060 to 1084) 173 bp ( 912 to 1084) 59.0°C
rgs4  U ATAGAGGAGTTGGTATTGTAGAGTGG ( 913 to 938) ACAACAAAAAAAACTATAACTTCAAC ( 1060 to 1085) 173 bp ( 913 to 938) 58.4°C
NM_003378 vgf  M GGATAGCGTTCGTAGGCG (–502 to –483) AAAAACCGAATTCCCCACCCCG (–430 to –418) GCGCCCAAAAACGACGTAAACCTAAATAC (–465 to –447)   85 bp (–502 to –418) 60.0°C
 




Heike Bernert passed the University Entrance Examination (Abitur) at Robert Schuman School 
in Saarlouis, Germany, in 1983. She studied Veterinary Medicine at the Free University of 
Berlin, School of Veterinary Medicine, Berlin, Germany, and earned her degree in veterinary 
medicine (equivalent to DVM degree) in 1991. She received her postgraduate training at 
Schering AG, Berlin, from 1991 to 1995. Based on her German doctoral dissertation 
“Investigation of the effectiveness of glutamate receptor antagonists using a brain trauma model 
in rats” she was awarded (magna cum laude) the professional degree of Dr.med.vet. (equivalent 
to Ph.D. degree) at the Free University of Berlin, School of Veterinary Medicine, Berlin, 
Germany, in 1998. 
 
She worked as a research fellow at the Free University of Berlin, School of Veterinary Medicine, 
Institute of Virology from 1996 to 1997. She was appointed as a veterinary expert at the Federal 
Institute for Drugs and Medical Devices (BfArM), Department of Clinical Pharmacology I, Unit 
for Infectious Diseases, Berlin, Germany, from 1998 to 2000. 
 
She joined The Ohio State University, Department of Medical Virology, Immunology, and 
Medical Genetics, Columbus, Ohio as a graduate research associate from 2000 to 2003 and The 
University of Tennessee, College of Veterinary Medicine, Department of Pathobiology, 
Knoxville, Tennessee from 2004 to 2006. From there, she went to The Johns Hopkins 
University, Division of Head and Neck Cancer Research, Department of Otolaryngology to 
pursue her doctorate in cancer epigenetics. 
 
 
 
